CURRICULUM VITAE – CHRISTIAN WEBER

GENERAL INFORMATION

Name:	Univ.-Prof. Dr. med. Christian Weber, DoB 15th October, 1967
Institute:	Ludwig-Maximilians-Universität München (LMU Munich) Institute for Cardiovascular Prevention (IPEK) Department of Medicine, Klinikum der Universität München (KUM) Pettenkoferstr. 9, 80336 Munich, Germany
Phone:	+49 (0)89 4400 54350
Email:	chweber@med.lmu.de
Web:	http://ipek.klinikum.uni-muenchen.de

ACADEMIC EDUCATION AND SCIENTIFIC DEGREES

2003 - 2004	Board Registration, Internal Medicine and Cardiology
1999	Venia legend (habilitation) in Experimental Internal Medicine, LMU Munich
1994	MD doctoral thesis (Dr. med.), LMU Munich
1986 - 1993	Study of Medicine at LMU Munich, Germany

SCIENTIFIC CAREER

2010 - present	Chair in Preventative Vascular Medicine (W3) and Director, Institute for Cardiovascular Prevention (IPEK), LMU Munich
2006 - present	Adjunct Professor, Dept. Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Masstricht University, Maastricht, The Netherlands
2005 - 2010	Chair of Molecular Cardiovascular Research (W3), Director, Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Germany
2001 - 2005	Professor of Molecular Cardiology (C3), Fellow Cardiology, Medical Clinic I (Prof. Dr. P. Hanrath), RWTH Aachen University, Germany
1997 - 2001	Fellow Internal Medicine, Medizinische Poliklinik (Prof. Dr. D. Schlöndorff), Group Leader DFG (*Deutsche Forschungsgemeinschaft*) Junior Research Group in Biosciences, LMU Munich
1995 - 1997	Postdoctoral DFG Research Fellow, Center for Blood Research (Prof. Dr. T. Springer), Dept. Pathology, Harvard Medical School, Boston, USA
1993 - 1994	Junior Fellow in Experimental Vascular Medicine, Institute for Cardiovascular Prevention (IPEK, Prof. Dr. P.C. Weber), LMU Munich

KEY FIGURES

703 publications, 430 original articles (125 first/last author), 273 review articles/commentaries

h-index 127 / 152, total citations 54,776 / 81,819 (Scopus/GoogleScholar)

COORDINATING FUNCTIONS, MEMBERSHIPS (selection)

2021 -	Speaker Munich Heart Alliance (MHA), partner site of the DZHK
2021 -	Principal Investigator of the DFG Excellence Cluster SyNergy
2018 - 2022	European Society of Cardiology (ESC) Basic Science Council (Vice-/Chair)
2014 - 2018	ESC Basic Science Council (Treasurer)
2011 - 2016	Coordinator, Leducq Transatlantic Network of Excellence *CVGeneF(x)*
2014 - 2026	Speaker, DFG Collaborative Research Centre SFB1123 *Atherosclerosis - mechanisms and networks of novel therapeutic targets*
2012 - 2014	Chair, ESC Working Group Atherosclerosis & Vascular Biology
2012	Senior Associate Editor, *Arteriosclerosis Thrombosis & Vascular Biology*
2011	Co-Speaker Munich Heart Alliance (MHA), partner site of the DZHK
2011	Member, International Society of Thrombosis & Haemostasis (ISTH, GTH)
2008 - 2010	Speaker, International Graduate School IRTG1508 *Arterial Remodeling*
2007 - 2014	Speaker, DFG program project grant FOR809 *Chemokines and adhesion molecules in cardiovascular pathogenesis*
2010	Editor-in-Chief *Thrombosis & Haemostasis*
2007 - 2008	President, Society of Microcirculation and Vascular Biology (GfMVB)
2004	Member American Heart Association (AHA), Basic Science Council
2004	Member & Fellow of the European Society of Cardiology (FESC)
2001	Member, German Cardiac Society (DGK)

AWARDS and HONORS (selection)

2023	European Atherosclerosis Society (EAS) Keynote Lecture
2022 - 2023	research.com ranking for biochemistry global #173, national #9
2022	William Harvey Lecture in Basic Science Award by the ESC
2019	Elected Member of the National Academy of Science Leopoldina
2018, **2020-2023**	Designated as ***Highly Cited Researcher*** (Cross-Field) by Clarivate Analytics
2016	European Research Council (ERC) Advanced Grant *PROVASC*
2016 - 2021	Listed #1 in worldwide expert ranking on atherosclerosis (ExpertScape)
2015	Alexander-Schmidt-Award, Society of Thrombosis & Haemostasis (GTH)
2010	ERC Advanced Grant *Atheroprotect*
2009	VICI Prize, Nederlandse Organisatie voor Wetenschappelijk Onderzoek
2009	AHA Special Recognition-Award
2009	Galenus-von-Pergamon-Award
2008	Paul-Martini-Award and ESC Outstanding Achievement-Award
2008	W.H. Hauss-Preis 2008, German Society of Atherosclerosis Research
2005	Forßmann-Award, University of Bochum
2004	Arthur-Weber-Award, German Cardiac Society
2003	Basic Science-Award, GlaxoSmithKline-Foundation

OTHER ACTIVITIES

Editor

2023 -	Associate Editor *Circulation*
2018	Guest Editor, *Circulation*
2014 - 2017	Consulting Editor, *Circulation Research*
2013 -	Regional Editor Europe, *Molecular Metabolism*
2012 - 2022	Senior Associate Editor, *Arteriosclerosis, Thrombosis & Vascular Biology*
2010 -	**Editor-in-Chief**, *Thrombosis & Haemostasis*

Editorial Boards
- *Basic Research in Cardiology, Cardiovascular Research, Circulation Research, EMBO Molecular Medicine, European Heart Journal*

Reviewer (selection)
- *Blood, Cell Metabol, Circulation, EMBO J, Immunity, J Clin Invest*
- *J Exp Med, J Am Coll Cardiol, Lancet, Nature, Nat Med, PNAS*
- *Science, Science Signal, Science Transl Med*

Reviewer (organisations)
- European Research Council (ERC), Consolidator Grant Panelist
- German Research Foundation (DFG), Suisse National Fund (SNF)
- MPG Minerva Foundation, Israel Science Foundation
- The Wellcome Trust, British Heart Foundation, Nobel Foundation

Scientific Advisory Boards
- Paris Cardiovascular Research Center (PARCC)
- Dept. Cardiologie, Universität Zürich (evaluation committee)
- *Carolus Therapeutics Inc.* (Chair SAB 2008-2016)
- *ProterixBio Inc.* (2014-2016)

Patents granted (B) Applications
- DE 10014516.1 (RANTES antagonists for treatment of restenosis)
- US 10411397 (JAM-1 small molecule antagonists and antibodies)
- DE 10328277.7 (customized parallel wall flow chamber)
- US8110552 **B2** & US8501680 **B2** (peptide antagonist CKEY2)
- US65701601 & WO2009117710 A2/A3 (MIF antagonists)
- US8337825 **B2** (GAG-antagonising MCP-1 mutants)
- WO 2009/073921 (microRNA and tissue repair)
- WO 2011/064354 A2 (MicroRNAs in atherosclerosis)
- EP 10001208.7-2406 (CCL17 inhibitors in T_{helper} cell-driven disease)
- EP2888228 **B1** (Inhibitors of CD40-TRAF6 interaction)
- US9750717 **B2** (Inhibitors of CD40-TRAF6 interaction)
- WO2017077062 A1 (peptide derived from human neutrophil peptide 1)
- EP3889262 A1 (Inhibition of caspase-3 by microRNA-126-5p)

Founder
- *Carolus Therapeutics Inc.*
- *Cartesio Therapeutics Inc.*

THIRD PARTY FUNDING (selection)

2023 - 2027	BMBF Cluster for Nucleic Acid Therapeutics Munich - WP8, budget 0.5 M€
2022 - 2026	DFG SFB1123 projects A1 (with Y. Döring), A10 (with J. Duchene), and Z3 *Chemokine receptors in atherosclerosis*, budget: 3.0 M€
2019 - 2027	DFG TR267 project A02 (with M. Sattler) miRNA regulation, budget 0.7 M€
2019 - 2023	DZHK – BHF grant (with J. Erdmann) *Molecular genetics*, budget: 0.4 M€
2019 - 2025	DFG Excellence Cluster SyNergy; PI funding, budget: 0.7 M€
2018 - 2022	DFG SFB1123 projects A1 (with Y. Döring), A10 (with J. Duchene), and Z3 *Chemokine receptors in atherosclerosis*, budget: 2.65 M€
2017 - 2019	DZHK HRHV grant (with E. Lutgens), *TRAF-STOPs*, budget: 0.6 M€
2017 - 2019	NIH grant 5R01HL122843-03 (with D. Saleheen), *CXCL12*, budget: 0.2 M€
2016 - 2021	ERC Advanced Grant °692511 *PROVASC*, budget: 2.5 M€
2014 - 2018	DFG SFB1123 projects A1 (with Y. Döring), B4 (with A. Schober), and Z3, *Chemokines and miRs in atherosclerosis*, budget: 2.2 M€
2011 - 2020	BMBF project MHA VD1.2 *Vascular Immunotherapy*, budget: 1.45 M€
2011 - 2016	NWO project VICI 918.10.616, *Chemokine interactome*, budget: 1.5 M€
2011 - 2016	Leducq Transatlantic Network of Excellence *CVGeneF(x)*, budget: 0.7 M€
2012 - 2015	BMBF grants TUR10/I13 & META JTC2011 *Metabolic stress*, budget: 0.4 M€
2012 - 2015	DFG SFB1054 project B04, *DC and Treg interactions*, budget: 0.45 M€
2012 - 2019	DFG SFB914 project B08 (with O. Söhnlein), *Differential recruitment of lekocyte subsets and role of alarmins*, budget: 0.9 M€
2011 - 2014	DFG program project FOR809, *Chemokines & adhesion molecules in cardiovascular pathogenesis* (P1-4/6/12, WE1913/10&12), budget: 3.5 M€
2010 - 2016	ERC Advanced Grant °249929 *Atheroprotect*, budget: 2.5 M€
2009 - 2013	DFG International Research Training Group GRK1508 *Euregio Cardiovascular Research School*, budget: 2.6 M€
2009 - 2011	DFG TR57 project P7 (with H. Wasmuth), *MIF and CXCR2*, budget: 0.1 M€
2008 - 2011	DFG SFB542 project A07 (with J. Bernhagen), A12 (with P. Mertens), *MIF receptor complexes, YB-1 & RANTES,* WE1913/13, budget: 1.0 M€
2007 - 2010	DFG program project FOR809, *Chemokines & adhesion molecules in cardiovascular pathogenesis* (P1-4/6, WE1913/10&12), budget: 2.5 M€
2006 - 2008	DFG project WE 1913/9, *JAM-A in atherosclerosis,* budget: 0.4 M€
2005 - 2008	DFG SFB542 project C12 (with P. Mertens), *YB-1 function,* budget: 0.25 M€
2004 - 2007	DFG project WE 1913/7-1&2 (with A. Schober), *SDF-1α and vascular progenitor cells,* budget: 0.2 M€
2003 - 2006	DFG project BE 1977/2-1 (with J. Bernhagen), *MIF in inflammatory processes and atherogensis,* budget: 0.1 M€
2003 - 2006	DFG project WE 1913/5-1, *Function of platelet chemokines*, budget: 0.25 M€
2001 - 2004	DFG project WE 1913/2-3, *Integrins and chemokines in atherogenic recruitment*, budget: 0.25 M€
1997 - 2001	Junior Research Group in Biosciences WE 1913/2-1&2 *Integrins & chemokine receptors: mechanisms and pathophysiology*, budget: 0.6 Mio. €

MENTORING (selection)

PhD students

cand. rer. nat. Maria Aslani (LMU München, current)
Dr. rer. nat. Carlos Neideck (‚summa cum laude', 2018, LMU München)
Dr. rer. nat. Manuela Mandl ('magna cum laude', 2017, LMU München)
Dr. rer. nat. Martin Schmitt (‚summa cum laude', 2014, RWTH Aachen)
Elena Vasina, PhD (2013, Maastricht University)
Dr. rer. nat. Sarawuth Wantha ('magna cum laude', 2013, RWTH Aachen)
Dr. rer. nat. Sakine Simsekyilmaz ('magna cum laude', 2012, RWTH Aachen)
Dr. rer. nat. Maik Drechsler ('magna cum laude', 2011, RWTH Aachen)
Dr. rer. nat. Yvonne Döring ('summa cum laude', 2011, RWTH Aachen)
Dr. rer. nat. Alisina Sarabi ('magna cum laude', 2011, RWTH Aachen)
Dr. rer. nat. Svenja Meiler ('summa cum laude', 2010, RWTH Aachen)
Dr. rer. nat. Regina Krohn ('summa cum laude', 2008, RWTH Aachen)
Dr. rer. medic. Elisa Liehn, MSc ('summa cum laude', 2008, RWTH Aachen
Dr. rer. nat. Line Fraemohs ('summa cum laude', 2007, RWTH Aachen)
Dr. rer. nat. Georg Ostermann ('summa cum laude', 2002, LMU München)
Dr. rer. hum. biol. Wolfgang Erl ('summa cum laude', 1996, LMU München)

MD students

cand. med. Julian Leberzammer (LMU München, current)
Dr. med. Veit Eckart ('summa cum laude', 2021, LMU München)
Dr. med. Sebastian Mause ('summa cum laude', 2011, RWTH Aachen)
Dr. med. Denis Gümbel ('summa cum laude', 2010, RWTH Aachen)
Dr. med. Yassin Djalali-Talab ('summa cum laude', 2009, RWTH Aachen)
Dr. med. Dipl.-Chem. Thomas Baltus ('summa cum laude', 2008 RWTH)
Dr. med. Ute Zeiffer ('summa cum laude', 2008 RWTH Aachen)
Dr. med. Britta Butzbach ('magna cum laude', 2006, RWTH Aachen)
Dr. med. Alma Zernecke ('summa cum laude', 2004, LMU München)
Dr. med. Tobias Weber ('summa cum laude', 2004, LMU München)
Dr. med. Philipp von Hundelshausen ('summa cum laude', 2003, LMU)
Dr. med. Celina Wardemann ('magna cum laude', 1998, LMU München)

Postdocs

Dr. rer. nat. Kiril Bidzhekov
Dr. rer. nat. Xavier Blanchet
Dr. rer. nat. Yvonne Döring
Dr. rer. nat. Johan Duchene
Dr. Virginia Egea
Dr. med. Chimge Günther
Dr. Remco Megens, PhD
Dr. rer. nat. Jiri Neuzil
Dr. rer. nat. Heidi Noels
Dr. rer. nat. Otilia Postea
Dr. med. Zuzanna Rowinska
Dr. med. Donato Santovito
Dr. Emiel van der Vorst, PhD
Dr. med. Felix Vogt

Habilitations

PD Dr. med. Philipp von Hundelshausen
PD Dr. med. Michael Hristov
PD Dr. ing. Rory Koenen
PD Dr. med. Elisa Liehn
PD Dr. med. Andreas Schober
PD Dr. med. Oliver Soehnlein, PhD
PD Dr. med. Alma Zernecke

Professors

Prof. Dr. Yvonne Döring (W2, Bern)
Prof. Dr. Norbert Gerdes (W2, Düsseldorf)
Prof. Dr. Esther Lutgens (AMC)
Prof. Dr. med. Donato Santovito (W2)
Prof. Dr. Andreas Schober (W2)
Prof. Dr. Oliver Söhnlein (W2/W3 Münster)
Prof. Dr. Alma Zernecke (W3, Würzburg)

BIBLIOGRAPHY (ORCID 0000-0003-4610-8714, WoS ID AAW-2153-2020)

10 most important original articles (citations: *GoogleScholar*)

1. Santovito D, Egea V, Bidzhekov K, Natarelli L, Mourão A, Wichapong K, Blanchet X, Aslani M, Horckmans M, Hristov M, Lutgens E, Daemen MJAP, Hackeng T, Ries C, von Hundelshausen P, Steffens S, Duchene J, Megens RTA, Sattler M, **Weber C**. Non-canonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. ***Sci. Transl. Med.*** 2020;12:eaaz2994. (*83 citations*).
2. von Hundelshausen P, Agten S, Eckardt V, Schmitt MMW, Blanchet X, Ippel H, Neideck C, Bidzhekov K, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen J, Li H, Leberzammer J, Naumann R, Dijkgraf I, Nicolaes G, Döring Y, Soehnlein O, Lutgens E, Heemskerk J, Koenen R, Mayo K, Hackeng T, **Weber C**. Structure-function mapping of the chemokine interactome enables tailored intervention in acute and chronic inflammation. ***Sci Transl Med*** 2017;9 (384): eaah6650 (*134 citations*).
3. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RTA, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, **Weber C**. MicroRNA-126-5p promotes endothelial proli-feration and limits atherosclerosis by suppressing Dlk1. ***Nat Med*** 2014;20:368-376 (*648 citations*).
4. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Nazari-Jahantigh M, Lutgens E, Wang S, Olson E, Schober A, **Weber C**. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. ***Sci Signal*** 2009;2:ra81 (*1542 citations*).
5. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini A, Kowalska A, Kungl AJ, Hackeng TM, Mayo KH, **Weber C**. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. ***Nat Med*** 2009;15:97-103 (*493 citations*).
6. Zernecke A, Bot I, Djalali Talab Y, Shagdarsuren E, Meiler S, Liehn EA, Schober A, Soehnlein O, Sperandio M, Tacke F, Biessen EA, **Weber C**. Protective role of Cxcr4/Cxcl12 unveils the importance of neutrophils in atherosclerosis. ***Circ Res*** 2008;102:209-217 (*505 citations*).
7. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, **Weber C**. MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. ***Nat Med*** 2007;13:587-596 (*1384 citations*).
8. Huo YQ, Schober A, Forlow SB, Smith D, Hyman M, Jung S, Littman DR, **Weber C**, Ley K. Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. ***Nat Med*** 2003;9:61-67 (*1250 citations*).
9. Ostermann G, Weber KSC, Zernecke A, Schröder A, **Weber C**. JAM-1 is a ligand for the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. ***Nat Immunol*** 2002;3:151-158 (*796 citations*).
10. von Hundelshausen P, Weber KSC, Huo YQ, Proudfoot A, Nelson PJ, Ley K, **Weber C**. Deposition of RANTES by platelets triggers monocyte recruitment on inflamed and atherosclerotic endothelium. ***Circulation*** 2001; 103:1772-1777 (*728 citations*).

Bibliometric parameters (*as per April 2024*)

Cumulative Impact factor (IF, 703 original and review articles):	6190.4
Cumulative IF (430 original articles):	4050.5
Cumulative IF (125 original articles as first/last author):	1343.1
Cumulative IF (273 review articles and commentaries):	2139.9
Average IF of Original articles (first/last author):	10.8
Total citations since 1996 (*Scopus*)	54,776
Total citations (*InCites/GoogleScholar*)	54,039 / 81,819
Citations p.a. between 2017 and 2023 (*Scopus/GoogleScholar*)	2926-4642 / 4514-6483
h-index/m-index *Scopus*	**127 / 3.9**
h-index *InCites*	**125**
h-index *GoogleScholar* (since 2019)	**152 (91)**
c-index (DOI: 10.17632/btchxktzyw.5; without self-citations)	**4.23**
c-index rank (of **all** *Scopus* author profiles, science-wide)	**#2903**

Publications in *NEJM, Nature*-, *Science*- and *Cell / Immunity*-Families (n=49)

1. Döring Y et al. & **Weber C** (2024) Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis. ***Nat. Cardiovasc. Res.*** 3:221-242.
2. Cimen I et al. & Santovito D, **Weber C** (2023) Targeting a ell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice. ***Sci. Transl. Med.*** 15:eadf3357.
3. Pekayvaz KA, et al. & **Weber C**, Libby P, Massberg S, Stark K (2023) Mural cells sustain a homeostatic vascular macrophage niche limiting chronic inflammation. ***Immunity***, in press.
4. Wagner JUG et al., **Weber C**, et al. & Zeiher AM, Brandes RP, Luxán G, Dimmeler S (2023) Ageing impairs the neurovascular interface in the heart. ***Science*** 381:897-906.
5. Wang Z et al. & **Weber C**, Habenicht AJR, Yin C (2023) Pairing of single-cell RNA analysis and T-cell receptor profiling reveals breakdown of T-cell tolerance checkpoints in atherosclerosis. ***Nat. Cardiovasc. Res.*** 2:290-306.
6. Guillamat-Prats R et al. & **Weber C**, Maegdefessel L, Faussner A, Hilgendorf I, Steffens S (2022) GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturation. ***Nat. Cardiovasc. Res.*** 1:1056-1071.
7. Tas K et al. & **Weber C**, Megens RT, Bernhagen J, Kapurniotu A (2022) Designed peptides as nanomolar cross-amyloid inhibitors acting via supramolecular nanofiber co-assembly. ***Nat. Commun.*** 13:5004.
8. Santovito D, **Weber C** (2022) Noncanonical features of microRNAs: paradigms emerging from cardio-vascular disease. ***Nat. Rev. Cardiol.*** 19:620-638.
9. Rot A et al. & **Weber C**, Duchene J (2022) Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1. ***Cell Stem Cell*** 29:1013-1015.
10. Mohanta SK et al. &, **Weber C***, Lembo G*, Carnevale D*, Habenicht AJR* (2022) Neuroimmune cardio-vascular interfaces control atherosclerosis. ***Nature*** 605:152-159. *equal contribution.
11. **Weber C**, Siess W, von Hundelshausen P (2021) VITT after ChAdOx1 nCOV-19 vaccination. ***N. Engl. J Med.*** 385:2202-2205.
12. Lacy M et al. & **Weber C**, Gerdes N, Atzler D, Lutgens E (2021) Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. ***Nat. Commun.*** 12:3754.
13. Kontos C et al. & **Weber C**, Kapurniotu A, Bernhagen J (2020) An engineered soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. ***Nat. Commun.*** 11:5981.
14. Bartelt A, **Weber C** (2020) Mitochondrial ejection for cardiac protection: the macrophage connection. ***Cell Metabol.*** 32:512-513.
15. Santovito D*, Egea V*, Bidzhekov K*, Natarelli L* et al. & Sattler M, **Weber C** (2020) Non-canonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. ***Sci. Transl. Med.*** 12:eaaz2994. *equal contribution.
16. Adrover JM et al. & **Weber C**, Lizasoaín I, Torres A, Ruiz-Cabello J, Vázquez J, Hidalgo A (2020) Pro-grammed “disarming” of the neutrophil proteome reduces the magnitude of inflammation. ***Nat. Immunol.*** 21:135-144.
17. Bianchini M, Duchêne J* et al. & **Weber C***, Megens RTA (2019) PD-L1 on non-classical monocytes reveals their origin and immuno-regulatory function. ***Sci. Immunol.*** 4:eaar3054. *corresponding author.
18. Silvestre-Roig C, Braster Q et al. & **Weber C**, Hidalgo A, Wong G, Nicolaes G, Soehnlein O (2019) Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. ***Nature*** 569:236-240.
19. Yin C, Ackermann S et al., **Weber C***, Zipfel PF*, Skerka C*, Habenicht AJR* (2019) ApoE attenuates un-resolvable inflammation by complex formation with activated C1q. ***Nat. Med.*** 25:496-506. *equal contribution.
20. Adrover J et al. & **Weber C**, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibáñez B, Hidalgo A (2019) A neutrophil clock coordinates immune defense and vascular protection. ***Immunity*** 50:390-402.
21. Braza MS et al. & **Weber C**, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WMJ, Ochando J (2018) Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. ***Immunity*** 49:819-828.

22. Winter C et al. & **Weber C**, Viola JR, Hidalgo A, Scheiermann C, Soehnlein O (2018) Chronopharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. ***Cell Metab.*** 28:175-182.

23. Soehnlein O, Steffens S, Hidalgo A, **Weber C** (2017) Neutrophils in immunity and immunopathology – protagonists and targets of chronic inflammation. ***Nat. Rev. Immunol.*** 17:248-261.

24. Krishnasamy K et al. & **Weber C**, Adams RH, Limbourg FP (2017) Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. ***Nat. Commun.*** 8:952.

25. Duchene J et al. & **Weber C***, Rot A* (2017) Atypical chemokine receptor 1 on nucleated erythroid cells regulates haematopoiesis. ***Nat. Immunol.*** 18:753-761. *corresponding authors.

26. von Hundelshausen P et al. & **Weber C** (2017) Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. ***Sci. Transl. Med.*** 9:eaah6650.

27. Gamrekelashvili J et al. & **Weber C**, Limbourg FP (2016) Regulation of monocyte cell fate by blood vessels. ***Nat. Commun.*** 7:12597.

28. Hartmann P et al. & **Weber C**, Schober A (2016) Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. ***Nat. Commun.*** 7:10521.

29. Finan B et al. & **Weber C**, Rozman J, Fuchs S, Gailus-Durner V, Hrabě de Angelis M, Hoffman SM, Gelfanov V, Yang B, Tschöp MH, DiMarchi R, Müller TD (2016) Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. ***Cell*** 167:843-857.

30. Schober A, Nazari-Jahantigh M, **Weber C** (2015) Mechanisms of microRNAs in atherosclerosis. ***Nat. Rev. Cardiol.*** 12:361-374.

31. Alard JE et al. & **Weber C**, Soehnlein O (2015) Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. ***Sci. Transl. Med.*** 7:317ra196.

32. Hu D et al. & **Weber C**, Lehmann T, Beer M, Grabner R, Maffia P, Weih F, Habenicht AJR (2015) ATLOs control aortic immunity and protect against atherosclerosis via VSMC-LTβ receptors. ***Immunity*** 42:1100-15. (***IF 24.082***)

33. Hinkel R et al. & **Weber C**, Bock-Marquette I, Olson EN, Posern G, Deindl E, Niemann H, Kupatt C (2014) MRTF-A mediates vessel growth and maturation via CCN1 and CCN2. ***Nat. Commun.*** 5:3970.

34. Schober A et al. & **Weber C** (2014) MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. ***Nat. Med.*** 20:368-376.

35. Casanova-Acebes M et al. & **Weber C**, Nagasawa T, Frenette PS, Castrillo A, Hidalgo A (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. ***Cell*** 153:1025–1035.

36. **Weber C**, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. ***Nat. Med.*** 17:1410-22

37. Zhou Z et al. & **Weber C**, Schober A (2011) Lipoprotein-derived lysophosphatidic acid enhances atherosclerosis through the release of CXCL1 from endothelium. ***Cell Metab.*** 13:592-600.

38. Soehnlein O et al. & **Weber C** (2011) Neutrophil-derived cathelicidin protects from neointimal hyperplasia. ***Sci. Transl. Med.*** 3:103ra98.

39. **Weber C** (2010) Far from the heart: receptor cross-talk in remote conditioning. ***Nat. Med.*** 16:760-762.

40. Goossens P et al. & **Weber C**, Lutgens E, de Winther MP (2010) Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. ***Cell Metab.*** 12:142-153.

41. Koenen RR, **Weber C** (2010) Therapeutic targeting of chemokine interactions in atherosclerosis. ***Nat. Rev. Drug Discov.*** 9:141-53.

42. Zernecke A et al. & **Weber C** (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. ***Sci. Signal.*** 2:ra81.

43. Koenen RR et al. & **Weber C** (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. ***Nat. Med.*** 15:97-103.

44. Choi EY et al. & **Weber C**, Chavakis T (2008) Del-1 is an endogenous inhibitor of leukocyte-endothelial adhesion preventing inflammatory cell recruitment. ***Science*** 322:1101-4.

45. **Weber C**, Zernecke A, Libby P (2008) The multifacetted contributions of leukocyte subsets to atherosclerosis. ***Nat. Rev. Immunol.*** 8:802-815.

46. Bernhagen J et al. & **Weber C** (2007) MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. ***Nat. Med.*** 13:587-596.

47. **Weber C**, Fraemohs L, Dejana E (2007) The role of junctional adhesion molecules in vascular inflammation. ***Nat. Rev. Immunol.*** 7:467-477.

48. Huo YQ, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, **Weber C**, Ley K (2003) Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. ***Nat. Med.*** 9:61-67.

49. Ostermann G, Weber KSC, Zernecke A, Schröder A, **Weber C** (2002) JAM-1 is a ligand for the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. ***Nat. Immunol.*** 3:151-158.

Original articles (selection, IF year of publication, °Clarivate top 1% in subject area)

1. Wang Y, Li G, Chen B, Shakir G, Volz M, van der Vorst EPC, Maas SL, Muley C, Bartelt A, Li Z, Sachs N, Maegdefessel L, Nazari-Jahantigh M, Hristov M, Lacy M, Enard W, Lutz B, **Weber C**, Herzig S, Guillamat Prats R, Steffens S (2023) Loss of myeloid cannabinoid receptor CB1 confers atheroprotection by reducing macrophage proliferation and immunometabolic reprogramming. ***Cardiovasc. Res.***, in press. ***(IF 10.8)***

2. Mueller TT, Thakur M, Wohlrab M, Meister S, Karaj F, Garcia Perez L, Öllinger R, Engleitner T, Langheinrich T, Völkl M, Zhang X, Tersteeg C, Mack M, Koedel U, Zigman Kohlmaier A, Teupser D, von Hundelshausen P, **Weber C**, Schulz C, Bortoluzzi S, Bernhagen J, Preissner KT, Rad R, Schmidt-Supprian M, Huber S, Massberg S, Ishikawa-Ankerhold H, Engelmann B (2023) Mutual regulation of $CD4^{+}$T cells and intravascular fibrin in infections. ***Haematologica (IF 10.5)***, in press.

3. Strohm L, Daiber A, Ubbens H, Krishnankutty R, Oelze M, Kuntic M, Hahad O, Klein V, Hoefer IE, von Kriegsheim A, Kleinert H, Atzler D, **Weber C**, Wild P, Münzel T, Knosalla C, Lutgens E, Daub S (2024) Role of inflammatory signaling pathways involving the CD40-CD40L-TRAF cascade in animal models of diabetes and hypertension as well as coronary artery disease patients with one or two of these comorbidities. ***Basic Res. Cardiol.***, in press. ***(IF 9.5)***

4. Vos WG, van Os BW, den Toom M, Beckers L, van Roomen C, van Tiel C, Band H, Nitz K, **Weber C**, Atzler D, de Winther MP, Bosmans LA, Lutgens E, Seijkens TT (2024) T cell specific deletion of Casitas B lineage lymphoma-b reduces atherosclerosis by enhancing T cell exhaustion. ***Front. Immunol.*** 15:1297893. (***IF 7.3***)

5. Döring Y, van der Vorst EPC, Yan Y, Neideck C, Blanchet X, Jansen Y, Kemmerich M, Bayasgalan S, Peters LJF, Hristov M, Bidzhekov K, Yin C, Zhang X, Leberzammer J, Park Y, Gencer S, Habenicht A, Faussner A, Teupser D, Monaco C, Holdt L, Santovito D, von Hundelshausen P, **Weber C** (2024) Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis. ***Nat. Cardiovasc. Res.*** 3:221-242

6. Cimen I, Natarelli L, Kichi ZA, Herndersen JM, Farina FM, Briem E, Aslani M, Megens RTA, Jansen Y, Mann_Fallenbuchel E, Gencer S, Duchene J, Nazari-Jahantigh M, van der Vorst EPC, Enard W, Döring Y, Schober A, Santovito D, **Weber C** (2023) Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice. ***Sci. Transl. Med.*** 15:eadf3357. ***(IF 17.1)***

7. Pekayvaz KA, Gold G, Hoseinpour P, Engel A, Coletti R, Joppich M, Janjic A, Knott M, Mehari F, Polewka V, Eivers L, Kirschner M, Martinez-Navarro A, Boda A, Nicolai L, Schulz H, Fingerle-Rowson G, Titova A, Kilani B, Lorenz M, Bucala R, Enard W, Zimmer R, Schulz C, **Weber C**, Libby P, Massberg S, Stark K (2023) Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation. ***Immunity*** 56:2325-2341. ***(IF 32.4)***

8. Sachs S, Götz A, Finan B, DiMarchi RD, Döring Y, **Weber C**, Tschöp MH, Müller TD, Hofmann SM (2023) GIP receptor agonism improves dyslipidemia & atherosclerosis independently of body weight in obese mice. ***Cardiovasc. Diabetol.*** 22:217. ***(IF 9.3)***

9. Wagner JUG, Tombor LS, Malacarne PF, Kettenhausen LM, Panthel J, Kujundzic H, Manickam N, Schmitz K, Cipca M, Stilz KA, Fischer A, Muhly-Reinholz M, Abplanalp WT, John D, Mohanta SK, **Weber C**, Habenicht AJR, Buchmann GK, Angendohr S, Amin E, Scherschel K, Klöcker N, Kelm M, Schüttler D, Clauss S, Guenther S, Boettger T, Braun T, Bär C, Pham MD, Krishnan J, Hille S, Müller OJ, Bozoglu T, Kupatt C, Nardini E, Osmanagic-Myers S, Meyer C, Zeiher AM, Brandes RP, Luxán G, Dimmeler S (2023) Ageing impairs the neuro-vascular interface in the heart. ***Science*** 381:897-906. ***(IF 56.9)***

10. Bosmans LA, van Tiel C, Aarts S, Willemsen L, Baardman J, den Toom M, Beckers L, Ahern D, Levels JHM, Jongejan A, Moerland PD, de Winther M, **Weber C**, Atzler D, Monaco C, Gerdes N, Shami A, Lutgens E (2023) Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state. ***Cardiovasc. Res.*** 119:1146–1160. ***(IF 10.8)***

11. Reiche ME, Poelsa K, Bosmans LA, van Tiel CM, Aarts SA, den Toom M, Beckers L, **Weber C**, Atzler D, Rensen PCN, Kooijman S, Lutgens E (2023) Adipose tissue controls haematopoiesis and inflammation through CD40 signaling. ***Haematologica*** 108:1873-1885. ***(IF 10.1)***

12. Wang Z, Zhang X, Zhang C, Ma Z, Lu S, Li Y, Sun T, Li Y, Hristov M, Steffens S, Santovito D, Mohanta S, Dornmair K, Ley K, **Weber C**, Habenicht A, Yin C (2023) Pairing of single-cell RNA analysis and T-cell receptor

profiling reveals breakdown of T-cell tolerance checkpoints in atherosclerosis. ***Nat. Cardiovasc. Res.*** 2:290-306.

13. Egea V, Megens RT, Santovito D, Wantha S, Brandl R, Siess W, Khani S, Soehnlein O, Bartelt A, **Weber C**, Ries C (2023) Properties and fate of human mesenchymal stem cells upon miRNA let-7f-promoted recruitment to atherosclerotic plaques. ***Cardiovasc. Res.*** 119:155-166. *(**IF 10.3**)*

14. Guillamat-Prats R, Hering D, Rami M, Härdtner C, Santovito D, Rinne P, Bindila L, Hristov M, Pagano S, Vuilleumier N, Schmid S, Janjic A, Enard W, **Weber C**, Maegdefessel L, Faussner A, Hilgendorf I, Steffens S (2022) GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturation. ***Nat. Cardiovasc. Res.*** 1:1056-1071.

15. Bosmans LA, van Tiel C, Aarts S, Willemsen L, Baardman J, den Toom M, Beckers L, Ahern D, Levels JHM, Jongejan A, Moerland PD, de Winther M, **Weber C**, Atzler D, Monaco C, Gerdes N, Shami A, Lutgens E (2022) Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state. ***Cardiovasc. Res.***, in press. *(**IF 13.081**)*

16. Nitz K*, Lacy M*, Wu Y, Preischl C, Bianchini M, Li Y, Forné I, Ammer C, Schwedhelm E, Huveneers S, Zimmer R, Imhof A, **Weber C**, Lutgens E, Atzler D (2022) Homoarginine supplementation ameliorates athe-rogenesis by modulating T-cell function. ***Circ. Res.*** 131:701-712. *equal contribution. *(**IF 23.213**)*

17. Tas K, Dalla Volta B, Lindner C, El Bounkari O, Hille K, Tian Y, Puig Bosch X, Ortner M, Prem S, Rammes G, **Weber C**, Megens RTA, Bernhagen J, Kapurniotu A (2022) Designed peptides as nanomolar cross-amyloid inhibitors acting via supramolecular nanofiber co-assembly. ***Nat. Commun.*** 13:5004. *(**IF 17.694**)*

18. ° Mohanta SK, Peng L, Li Y, Yin C, Lu S, Sun T, Carnevale L, Perrotta M, Ma Z, Förster B, Stanic K, Zhang C, Zhang X, Szczepaniak P, Bianchini M, Saeed B, Carnevale R, Hu D, Nosalski R, Pallante F, Beer M, Santovito D, Ertürk A, Mettenleiter TC, Klupp BG, Megens RTA, Steffens S, Pelisek J, Eckstein HH, Kleemann R, Habenicht L, Mallat Z, Michel J, Bernhagen J, Dichgans M, D´Agostino G, Guzik T, Olofsson P, **Weber C***, Lembo G*, Carnevale D*, Habenicht AJR* (2022) Neuroimmune cardiovascular interfaces form atherosclerosis brain circuits. ***Nature*** 605:152-159. *equal contribution. *(**IF 69.504**, 66 citations)*

19. Rot A, Biswas A, Hub E, Guthjar J, Aslani M, Thiriot A, von Andrian U, Megens RTA, **Weber C**, Duchene J (2022) Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1. ***Cell Stem Cell*** 29:1013-1015. *(**IF 25.269**)*

20. Bozoglu T, Lee S, Ziegler T, Jurisch V, Maas S, Bähr A, Hinkel R, Hoenig A, Hariharan A, Decker S, Sami H, Koppara T, Oellinger R, Müller OJ, Frank D, Megens R, Nelson P, **Weber C**, Schnieke A, Sperandio M, Santamaria G, Rad R, Moretti, Laugwitz KL, Soehnlein O, Ogris M, Kupatt C (2022) Endothelial retargeting of AAV9 in vivo. ***Adv. Sci.*** 9:e2103867.*(**IF 17.521**)*

21. **Weber C**, von Hundelshausen P, Siess W (2021) VITT after ChAdOx1 nCOV-19 vaccination. ***N. Engl. J Med.*** 385:2202-2205. *(**IF 176.079**)*

22. Hinterdobler J, Schott S, Meesmann A, Steinsiek AL, Zimmermann AS, Wobst J, Vilne B, Jin H, Baecklund A, Chen CS, Moggio A, Braster Q, Molitor S, Hristov M, **Weber C**, Wenzel P, Scheiermann C, Maegdefessel L, Soehnlein O, Libby P, Nahrendorf M, Schunkert H, Kessler T, Sager HB (2021) Acute mental stress promotes inflammatory leukocyte migration to tissues. ***Eur. Heart J.*** 42:4077-4088. *(**IF 35.855**)*

23. Schober A, Blay RM, Saboor Maleki S, Zahedi F, Winkelmaier A, Kakar M, Baatsch I, Zhu M, Geissler C, Fusco A, Eberlein A, Li N, Megens RTA, Banafsche R, Kumbrink J, **Weber C**, Nazari-Jahantigh (2021) MicroRNA-21 controls the circadian regulation of apoptosis in atherosclerotic lesions. ***Circulation*** 144:1059-1073. *(**IF 39.918**)*

24. Hinkel R, Baktai S, Baehr A, Bozoglu T, Straub S, Borchert T, Viereck J, Howe A, Hornaschewitz N, Jurisch V, Kozlik-Feldmann R, Freudenthal F, Ziegler T, **Weber C**, Sperandio M, Engelhardt S. Laugwitz KL, Moretti A, Klymiuk N, Thum T, Kupatt C (2021) AntimiR-132 inhibits transition to pathologic hypertrophy in a large animal model of percutaneous aortic constriction. ***J. Am. Coll. Cardiol.*** 77:2923-2935. (***IF 27.203***)

25. Lacy M, Bürger C, Ahmadsei M, Winkels H, Nitz K, van Tiel C, Seijkens T, Kusters P, Karshovka E, Reim S, Kuipers M, Reiche M, Megens R, Heemskerk J, **Weber C**, Gerdes N, Atzler D, Lutgens E (2021) Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. ***Nat. Commun.*** 12:3754. *(**IF 17.694**)*

26. Shami A, Atzler D, Bosmans L, Winkels H, Meiler S, Lacy M, van Tiel C, Megens R, Nitz K, Baardman J, Buerger C, Janjic A, Riccardi C, Edsfeldt A, Monaco C, Daemen M, de Winther M, Nilsson J, **Weber C**, Gerdes N, Gonçalves I, Lutgens E (2020) Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. ***Eur. Heart J.*** 41:2938-2948. *(**IF 29.983**)*

27. Hamid SM, Citir M, Terzi E, Cimen I, Yildirim Z, Dogan AE, **Weber C**, Traynor-Kaplan A, Schultz C, Erbay E (2020) Mammalian inositol-requiring enzyme-1 regulates phosphoinositide signaling lipids and cell growth. ***EMBO Reports*** e51462. *(**IF 8.807**)*

28. Kontos C, El Bounkari O, Krammer C, Sinitski D, Hille K, Zan C, Guangyao Y, Wang S, Brandhofer M, Bourilhon P, Megens RTA, Hoffmann A, Asare Y, Gao Y, Leng L, Mägdefessel L, Eckstein H, Pelisek J, Gokce O, Bucala R, Dichgans M, **Weber C**, Kapurniotu A, Bernhagen J (2020) An engineered soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. ***Nat. Commun.*** 11:5981. *(**IF 14.919**)*

29. Santovito D*, Egea V*, Bidzhekov K*, Natarelli L*, Mourão A, Wichapong K, Blanchet X, Aslani M, Horck-mans M, Hristov M, Lutgens E, Daemen MJAP, Hackeng T, Ries C, von Hundelshausen P, Steffens S, Duchene J, Megens RTA, Sattler M, **Weber C** (2020) Non-canonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. ***Sci. Transl. Med.*** 12:eaaz2994. (***IF 17.956***, *83 citations*)

30. Döring Y, Cimen I, Jansen Y, Aslani M, Gencer S, Peters LJF, Duchene J, **Weber C***, van der Vorst EPC* (2020) B-cell specific CXCR4 protects against atherosclerosis development and increases plasma IgM levels. ***Circ. Res.*** 126:787-788. *(**IF 17.367**)* *equal contriubtion.

31. Eckardt V, Miller MC, Blanchet X, Leberzammer J, Duchene J, Söhnlein O, Megens RTA, Ludwig AK, Dregni A, Faussner A, Wichapong K, Ippel H, Dijkgraaf I, Hackeng TM, **Weber C**, Gabius HJ, Mayo KH, von Hundelshausen P (2020) Chemokines and galectins form heterodimers to modulate inflammation. ***EMBO Reports*** 21:e47852. *(**IF 8.807**)*

32. Hinkel R, Ramanujam D, Kazcmarek V, Howe A, Klett K, Beck C, Dueck A, Thum T, Laugwitz KL, Maegdefessel L, **Weber C**, Kupatt C, Engelhardt S (2020) Inhibition of microRNA-21 prevents myocardial re-modelling and dysfunction in a pig model of ischemia/reperfusion injury-induced heart failure. ***J. Am. Coll. Cardiol.*** 75:1788-1800. (***IF 24.094***)

33. ° Adrover JM, Aroca-Crevillén A, Crainiciuc G, Ostos F, Rojas-Vega Y, Rubio-Ponce A, Cilloniz C, Bonzón-Kulichenko E, Calvo E, Rico D, Moro MA, **Weber C**, Lizasoaín I, Torres A, Ruiz-Cabello J, Vázquez J, Hidalgo A (2020) Programmed “disarming” of the neutrophil proteome reduces the magnitude of inflammation. Nat. Immunol. 21:135-144. (***IF 25.606***)

34. Bianchini M, Duchêne J*, Santovito D, Schloss MJ, Evrard M, Winkels H, Aslani M, Mohanta SK, Horckmans M, Blanchet X, Lacy M, von Hundelshausen P, Atzler D, Habenicht A, Gerdes N, Pelisek J, Ng LG, Steffens S, **Weber C***, Megens RTA (2019) PD-L1 on non-classical monocytes reveals their origin and immunoregulatory function.. ***Sci. Immunol.*** 4:eaar3054. *corresponding author. *(**IF 13.440**)*

35. ° Silvestre-Roig C, Braster Q, Wichapong K, Ernest Y, Lee E, Teulon JM, Berrebeh N, Winter J, Adrover JM, Santos GS, Froese A, Lemnitzer P, Ortega-Gómez A, Chevre R, Marschner J, Schmuski A, Winter C, Perez-Olivares, Chang P, Paulin N, Schoufour T, Hartwig H, González Ramos S, Kamp F, Megens RTA, Mowen KA, Gunzer M, Maegdefessel L, Hackeng T, Lutgens E, Daemen M, von Blume J, Anders HJ, Nikolaev V, Pellequer JL, **Weber C**, Hidalgo A, Wong G, Nicolaes G, Soehnlein O (2019) Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. ***Nature*** 569:236-240. *(**IF 42.778**) (286 citations)*

36. ° Yin C*, Ackermann S*, Mohanta SK, Ma Z, Nietzsche S, Westermann M, Peng L, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Eckstein HH, Pelisek J, Herms J, Röber S, Arzberger T, Habenicht L, Binder C, **Weber C***, Zipfel PF*, Skerka C*, Habenicht AJR* (2019) ApoE attenuates unresolvable inflammation by complex formation with activated C1q. ***Nat. Med.*** 25:496-506. *equal contribution. *(**IF 36.130**, 213 citations)*

37. ° Döring Y, van der Vorst EPC, Duchene J, Jansen Y, Gencer S, Bidzhekov K, Atzler D, Santovito D, Rader DJ, Saleheen D, **Weber C** (2019) CXCL12 derived from endothelial cells promotes atherosclerosis to drive coronary artery disease. ***Circulation*** 139:1338-1340 *(**IF 23.603**)*

38. ° Cremer S, Michalik K, Pfisterer L, Winter C, Boon R, Fischer A, Jaé N, Muhly-Reinholz M, John D, Uchida S, **Weber C**, Poller W, Günther S, Braun T, Li Y, Maegdefessel L, Perisic Matic L, Hedin U, Soehnlein O, Zeiher A, Dimmeler S (2019) Hematopoietic deficiency of the long non-coding RNA MALAT1 promotes atherosclerosis and plaque inflammation. ***Circulation*** 139:1320-1334. *(**IF 23.603**)*

39. ° Adrover JM, Del Fresno C, Crainiciuc G, Cuartero MI, Casanova-Acebes M, Weiss LA, Huerga-Encabo H, Silvestre-Roig C, Rossaint J, Cossío I, Lechuga-Vieco AV, García-Prieto J, Gómez-Parrizas M, Quintana JA, Ballesteros I, Martin-Salamanca S, Aroca-Crevillen A, Chong SZ, Evrard M, Balabanian K, López J, Bidzhekov K, Bachelerie F, Abad-Santos F, Muñoz-Calleja C, Zarbock A, Soehnlein O, **Weber C**, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibáñez B, Hidalgo A. (2019) A neutrophil timer coordinates immune defense and vascular protection. ***Immunity*** 50:390-402. (***IF 22.553***)

40. Seijkens TTP, Poels K, Meiler S, van Tiel CM, Kusters PJH, Reiche M, Atzler D, Winkels H, Tjwa M, Poelman H, Slütter B, Kuiper J, Gijbels M, Kuivenhoven JA, Perisic Matic L, Paulsson-Berne G, Hedin U, Hansson GK, Nicolaes GA, Daemen MAJP, **Weber C**, Gerdes N, de Winther M, Lutgens E (2019) Deficiency of the T cell regulator CBL-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death. ***Eur. Heart J.*** 40:372-382. *(**IF 22.673**)*

41. Baaten CCF, Meacham S, de Witt SM, Feijge MAH, Adams DJ, Akkerman JW, Cosemans JM, Jupe S, Kostadima M, Mattheij NJA, Prins MH, Ramirez-Solis R, Soehnlein O, **Weber C**, White JK, Ouwehand WH, Heemskerk JWM (2018) A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding. ***Blood*** 132:e35-e46. *(**IF 16.562**)*

42. Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJ, Pérez-Medina C, Conde P, Garcia M, Gonzalez-Perez M , Brahmachary M, Fay F, Kluza E, Kossatz S, Dress R, Salem F, Rialdi A, Reiner T, Boros P, Strijkers G, Calcagno C, Ginhoux F, Marazzi I, Lutgens E, Nicolaes G, **Weber C**, Swirski F, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea M, Mulder WM, Ochando J (2018) Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. ***Immunity*** 49:819-828. (***IF 21.522***)

43. ° Casanova-Acebes M, Nicolás-Ávila JA, Weiss LA, Adrover JM, A-González N, Devi S, Mortha A, Quintana J, Crainiciuc J, Leiva MN, **Weber C**, Nagasawa T, Soehnlein O, Merad M, Ng L, Hidalgo A (2018) Neutrophils instruct homeostatic and pathological states in naive tissues. ***J. Exp. Med.*** 215:2778-95. *(**IF 10.892**)*

44. Paulin N, Viola JR, Maas SL, de Jong R, Fernandes-Alnemri T, **Weber C**, Drechsler M, Döring Y, Soehnlein O (2018) Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability. ***Circulation*** 138:321-323. *(**IF 23.054**)*

45. Winter C, Silvestre-Roig C, Ortega-Gomez A, Lemnitzer P, Poelmann H, Schumski A, Winter J, Drechsler M, de Jong R, Immler R, Sperandio M, Hristov M, Zeller T, Nicolaes GAF, **Weber C**, Viola JR, Hidalgo A, Scheiermann C, Soehnlein O (2018) Chrono-pharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. ***Cell Metab.*** 28:175-182. *(**IF 22.415**)*

46. Busygina K, Jamasbi J, Seiler T, Deckmyn H, **Weber C**, Brandl R, Lorenz R, Siess W (2018) Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation. ***Blood***, 131:2605-2616 *(**IF 16.562**)*

47. Horckmans M, Bianchini M, Santovito D, Megens R, Springael JY, Vacca M, Di Eusanio M, Moschetta A, **Weber C**, Duchene J, Steffens S (2018) Pericardial adipose tissue regulates granulopoiesis, fibrosis and cardiac function after myocardial infarction. ***Circulation*** 137:948-960. *(**IF 23.054**)*

48. Seijkens TTP, van Tiel CM, Atzler D, Kusters PJ, Zarzycka B, Lameijer M, Soehnlein O, Hoeksema M, Gijbels MJ, Beckers L, den Toom M, Schrijver R, Boon L, Fay F, Jongejan A, Moerland PD, Vriend G, Bleij-levens B, Fisher EA, Duivenvoorden R, Gerdes N, de Winther MP, Nicholaes GA, Mulder WJ, **Weber C**, Lutgens E (2018) Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. ***J. Am. Coll. Cardiol.*** 71:527-542. (***IF 18.639***)

49. Winkels H, Meiler S, Smeets E, Lievens D, Engel D, Spitz C, Bürger C, Beckers L, Dandl A, Reim S, Ahmadsei M, Hartwig H, Holdt L, Hristov M, Megens RTA, Schmitt MM, Biessen EA, Borst J, Faussner A, **Weber C**, Lutgens E, Gerdes N (2017) CD27 co-stimulation increases frequency of regulatory T cells and re-duces atherosclerosis in hyperlipidemic mice. ***Eur. Heart J.*** 38:3590-3599. *(**IF 23.425**)*

50. Krishnasamy K, Limbourg A, Kapanadze T, Gamrekelashvili J, Beger C, Häger C, Falk C, Napp LC, Bauersachs J, Mack M, Haller H, **Weber C**, Adams RH, Limbourg FP (2017) Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. ***Nat. Commun.*** 8:952. ***(IF 12.353)***

51. Döring Y, Noels H, van der Vorst EPC, Egea V, Drechsler M, Mandl M, Neideck C, Pawig L, Jansen J, Schröder K, Bidzhekov K, Megens R, Theelen W, Klinkhammer BM, Boor P, Schurgers L, van Gorp R, Ries C, Kusters PJH, van der Wal A, Hackeng T, Gäbel G, Brandes RP, Soehnlein O, Lutgens E, Vestweber D, Teupser D, Holdt LM, Rader DJ, Saleheen D, **Weber C** (2017) Vascular CXCR4 limits atherosclerosis by maintaining arterial integrity. ***Circulation*** 136:388-403. ***(IF 18.881**, 151 citations)*

52. Rinne P, Rami M, Nuutinen S, Lyytikäinen LP, Raitoharju E, Oksala N, Ring L, Cai M, Hruby VJ, Lehtimäki T, **Weber C**, Steffens S (2017) Melanocortin 1 receptor signaling regulates cholesterol transport in macrophages. ***Circulation*** 136:83-97. ***(IF 18.881)***

53. Duchene J, Novitzky-Basso I, Casanova-Acebes M, Bianchini M, Etheridge SL, Hub E, Nitz K, Thiriot A, Ulvmar MH, Bacon A, Bidzhekov K, Ruelicke T, Caamano J, Moss PAH, Megens R, von Andrian UH, Hidalgo A, **Weber C***, Rot A* (2017) Atypical chemokine receptor 1 on nucleated erythroid cells regulates haematopoiesis. ***Nat. Immunol.*** 18:753-761. *corresponding authors. ***(IF 21.809)***

54. von Hundelshausen P, Agten S, Eckardt V, Schmitt MMW, Blanchet X, Ippel H, Neideck C, Bidzhekov K, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen J, Li H, Leberzammer J, Naumann R, Dijkgraf I, Nicolaes G, Döring Y, Soehnlein O, Lutgens E, Heemskerk J, Koenen R, Mayo K, Hackeng T, **Weber C** (2017) Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. ***Sci. Transl. Med.*** 9:eaah6650. (***IF 16.710**, 134 citations)*

55. Asare Y, Azombo FA, Schmitz C, Lue H, Tilstam PV, Gessner A, Lange D, **Weber C**, Dichgans M, Jan-kowski J, Pardi R, de Winther MPJ, Noels H, Bernhagen J (2017) Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo. ***Proc. Natl. Acad. Sci. USA.*** 114:E2766-E2775. (***IF 9.504)***

56. Tufanli O, Telkoparan P, Acosta-Alvear D, Hamid SM, Onat UI, Kocaturk B, Cimen I, Walter P, **Weber C**, Erbay E (2017) Targeting IRE1 with small molecules counteracts progression of atherosclerosis. ***Proc. Natl. Acad. (IF 9.504)***

57. ° Horckmans M, Ring L, Duchene J, Santovito D, Schloss M, Drechsler M, **Weber C**, Soehnlein O, Steffens S (2017) Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. ***Eur. Heart J.*** 38:187-197. ***(IF 23.425**, 616 citations)*

58. Agten SM, Koenen RR, Ippel H, Eckardt V, von Hundelshausen P, Mayo KH, **Weber C**, Hackeng TM (2016) Probing functional heteromeric chemokine protein-protein interactions through conformation-assisted oxime-linkage. ***Angew. Chem. Int. Ed. Engl.*** 55:14963-14966. ***(IF 11.994)***

59. Chong SZ, Evrard M, Devi S, Chen J, Lim Y, See P, Zhang Y, Adrover J, Lee B, Tan L, Li J, Liong K, Phua C, Balachander A, Boey A, Liebl D, Tan S, Chan J, Balabanian K, Harris JE, Bianchini M, Duchene J, **Weber C**, Lum J, Poidinger M, Renia L, Wang C, Larbi A, Randolph GJ, Weninger W, Looney M, Krummel M, Biswas S, Ginhoux F, Hidalgo A, Bachelerie F, Ng LG (2016) CXCR4 identifies transitional bone marrow pre-monocytes that replenish the mature monocyte pool for peripheral responses. ***J. Exp. Med.*** 213:2293-2314. ***(IF 11.991)***

60. Finan B, Clemmensen C, Zhu Z, Vanacker K, Müller L, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Flamant D, Biebermann H, Döring Y, **Weber C**, Rozman J, Fuchs S, Gailus-Durner V, Hrabě de Angelis M, Hoffman SM, Gelfanov V, Yang B, Tschöp MH, DiMarchi R, Müller TD (2016) Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. ***Cell*** 167:843-857. ***(IF 30.410)***

61. Ortega-Gomez A, Salvermoser M, Rossaint J, Pick R, Brauner J, Lemnitzer P, Tilgner J, de Jong R, Megens R, Jamasbi J, Döring Y, Pham C, Scheiermann C, Siess W, Drechsler M, **Weber C**, Grommes J, Zarbock A, Walzog B, Soehnlein O (2016) Cathepsin G controls arterial but not venular myeloid cell recruitment. ***Circulation*** 134:1176-1188. ***(IF 19.309)***

62. Viola, JR, Lemnitzer P, Jansen Y, Winter C, Neideck C, Silvestre-Roig C, Döring Y, Drechsler M, **Weber C**, Cenac N, Soehnlein O (2016) Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogresion in mice. ***Circ. Res.*** 119:1030-1038. (***IF 13.965***)

63. Gamrekelashvili J, Giagnorio R, Jussofie J, Soehnlein O, Duchene J, Briseño CG, Ramasamy SK, Krishnasamy K, Limbourg A, Kapanadze T, Ishifune C, Hinkel R, Radtke F, Strobl LJ, Zimber-Strobl U, Napp LC, Bauersachs J, Haller H, Yasutomo K, Kupatt C, Murphy KM, Adams RH, **Weber C**, Limbourg FP (2016) Regulation of monocyte cell fate by blood vessels. ***Nat. Commun.*** 7:12597. ***(IF 12.124)***

64. Li J, McArdle S, Gholami A, Kimura T, Wolf D, Gerhardt T, Miller J, **Weber C**, Ley K (2016) CCR5+T-bet+ FoxP3+ effector CD4 T cells drive atherosclerosis. ***Circ. Res.*** 118:1540-52. (***IF 13.965***)

65. Hartmann P, Zhou Z, Natarelli L, Nazari-Jahantigh M, Wei Y, Zhu M, Grommes J, Steffens S, **Weber C**, Schober A (2016) Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. ***Nat. Commun.*** 7:10521. ***(IF 12.124)***

66. Alard JE, Ortega-Gomez A, Wichapong K, Bongiovani D, Horckmanns M, Megens RTA, Leoni G, Ferraro B, Rossaint J, Paulin N, Hinkel R, Blanchet X, Gaillard F D'Amico M, von Hundelshausen P, Zarbock A, Scheiermann C, Hackeng TM, Steffens S, Kupatt C, Nicolaes GAF, **Weber C**, Soehnlein O (2015) Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. ***Sci. Transl. Med.*** 7:317ra196. (***IF 16.264***)

67. ° Soehnlein O, Ortega-Gómez A, Döring Y, **Weber C** (2015) Neutrophil-macrophage interplay in atherosclerosis: protease-mediated cytokine processing versus NET release. ***Thromb. Haemost.*** 114:866-7. ***(IF 5.255)***

68. Medina I, Cougole C, Drechsler M, Bermudez B, Koenen RR, Wolfs I, Doering Y, Herias V, Gijbels M, Bot I, de Jager S, Moscai A, **Weber C**, Cleutjens J, van Berkel TJC, Maridonneau-Parini I, Soehnlein O, Biessen EAL (2015) Hck/Fgr kinase deficiency reduces plaque growth and stability by blunting monocyte recruitment and intraplaque motility. ***Circulation*** 132:490-501. ***(IF 17.202)***

69. Hu D, Mohanta SK, Peng L, Yin C, Srikakulapu P, Grassia G, MacRitchie N, Dever G, Gordon P, Burton FL, Ialenti A, Sabir SR, McInnes IB, Brewer JM, Garside P, **Weber C**, Lehmann T, Beer M, Grabner R, Maffia P, Weih F, Habenicht AJR (2015) ATLOs control aortic immunity and protect against atherosclerosis via VSMC-LTβ receptors. ***Immunity*** 42:1100-15. (***IF 24.082***)

70. Jamasbi, J, Megens R, Münch G, Ungerer M, Faussner A, Lorenz R, Sherman S, Walker A, Gojal P, **Weber C**, Brandl R, Jung S, Farndale R, Elia N, Siess W (2015) Inhibition of platelet activation in blood exposed to atherosclerotic plaques by GPVI-Fc and anti-GPVI antibodies: functional and imaging studies. ***J. Am. Coll. Cardiol.*** 65:2404-15. (***IF 17.759***)

71. Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, Wang JM, Grommes J, Hinkel R, Kupatt C, **Weber C**, Döring Y, Zarbock A, Soehnlein O (2015) Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. ***Circ. Res.*** 116:827-35. (***IF 11.551***)

72. Karshovska E, Zhao Z, Blanchet X, Schmitt M, Bidzhekov K, Soehnlein O, von Hundelshausen P, Mattheij NJA, Cosemans JM, Megens RTA, Koeppel TA, Schober A, Hackeng TM, **Weber C**, Koenen RR (2015) Hyperreactivity of junctional adhesion molecule A-deficient platelets accelerates atherosclerosis in hyperlipidemic mice. ***Circ. Res.*** 116:587-99. (***IF 11.551***)

73. Hinkel R, Trenkwalder T, Petersen B, Stachel G, Lee, S, Husada W, Gesenhues F, Hannappel E, DiMaio JM, Hatzopoulos AK, Theisen D, Boekstegers P, LeNoble F, Nordheim A, Reichart B, **Weber C**, Bock-Marquette I, Olson EN, Posern G, Deindl E, Niemann H, Kupatt C (2014) MRTF-A mediates vessel growth and maturation via CCN1 and CCN2. ***Nat. Commun.*** 5:3970. ***(IF 11.470)***

74. Noels H, Zhou B, Tilstam P, Theelen W, Li X, Akhtar S, Simsekyilmaz S, Liehn E, Schober A, Adams R, Bernhagen J, Döring Y, **Weber C** (2014) Deficiency of endothelial Cxcr4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in mice. ***Arterioscler. Thromb. Vasc. Biol.*** 34:1209-20. ***(IF 6.008)***

75. Rossaint J, Herter J, van Aken H, Napirei M, Döring Y, **Weber C**, Soehnlein O, Zarbock A (2014) Synchronized integrin and chemokine activation is crucial in neutrophil extracellular trap-mediated acute lung injury. ***Blood*** 123:2573-84. ***(IF 10.452)***

76. ° Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RTA, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, **Weber C** (2014) MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. ***Nat. Med.*** 20:368-376. (comment in *Sci. Transl. Med.* 6:230ec57*; Arterioscler. Thromb. Vasc. Biol.* 2014;34:e15-6; recommended in F1000 prime) ***(IF 28.223,*** *644 citations)*

77. Li X, Penfold M, Megens R, Koenen RR, Thiemann A, Heyll K, Akhtar S, van Zandvoort M, Schall TJ, **Weber C***, Schober A* (2014) Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue. ***Circulation*** 129:1244-53. *corresponding authors. *(**IF 15.073**)*

78. Döring Y, Noels H, Mandl M, Kramp B, Lievens D, Drechsler M, Megens R, Tilstam PV, Langer M, Hartwig H, Sperandio M, Söhnlein O, **Weber C** (2014) Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest. ***Circ. Res.*** 114:976-981. (comment in *Circ. Res.* 114:935-937) (***IF 11.019***)

79. ° Hartwig H, Drechsler M, Lievens D, Kramp B, von Hundelshausen P, Lutgens E, **Weber C**, Döring Y, Soehnlein O (2014) Platelet-derived PF4 reduces neutrophil apoptosis in inflammation. ***Thromb. Haemost.*** 111:562-4. *(**IF 4.984**)*

80. Chèvre R, González-Granado JM, Megens RT, Sreeramkumar V, Silvestre-Roig C, Molina-Sanchez P, **Weber C**, Soehnlein O, Hidalgo A, Andrés V (2014) High-resolution imaging of intravascular atherogenic inflammation in live mice. ***Circ. Res.*** 114:770-9. (***IF 11.019***)

81. Schmitt MMN, Megens RTA, Zernecke A, Bidzhekov K, van den Akker NM, Rademakers T, van Zandvoort MA, Hackeng TM, Koenen RR, **Weber C** (2014) Endothelial JAM-A guides monocytes into flow-dependent predilection sites of atherosclerosis. ***Circulation*** 129:66-76. *(**IF 15.073**)*

82. Lievens D, Habets KL, Robertson AK, Laouar Y, Winkels H, Rademakers T, Beckers L, Wijnands E, Boon L, Mosaheb M, Ait-Oufella H, Mallat Z, Flavell RA, Rudling M, Binder C, Gerdes N, Biessen EAL, **Weber C**, Daemen MJAP, Kuiper J, Lutgens E (2013) Abrogated transforming growth factor-β receptor II (TGFβRII) signaling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. ***Eur. Heart J.*** 34:3717-27. (comment in *Eur. Heart J.* 34:3684) *(**IF 14.723**)*

83. Liehn E, Kanzler I, Konschalla S, Kroh A, Simsekyilmaz S, Sönmez T, Bucala R, Bernhagen J, **Weber C** (2013) Compartmentalized protective versus detrimental effects of endogenous MIF mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion. ***Arterioscler. Thromb. Vasc. Biol.*** 33:2180-86 *(**IF 5.533**)*

84. ° Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chèvre R, A-González N, Kunisaki Y, Zhang D, van Rooijen N, Silberstein L, **Weber C**, Nagasawa T, Frenette PS, Castrillo A, Hidalgo A (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. ***Cell*** 153:1025–1035. *(**IF 33.116**, 650 citations)*

85. Wei Y, Nazari-Jahantigh M, Heyll K, Thiemann A, Chan L, **Weber C**, Schober A (2013) The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. ***Circulation*** 127:1609-1619. *(**IF 14.948**)*

86. Soehnlein O, Drechsler M, Döring Y, Lievens D, Hartwig H, Kemmerich K, Ortega-Gómez A, Mandl M, Vijayan S, Projahn D, Garlichs CD, Koenen RR, Hristov M, Lutgens E, Zernecke A, **Weber C** (2013) Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. ***EMBO Mol. Med.*** 5:471-481. *(**IF 8.245**, 224 citations)*

87. Wantha S, Alard JE, Megens RTA, van der Does A, Döring Y, Drechsler M, Pham CT, Wang MW, Wang JM, Gallo RL, von Hundelshausen P, Lindbom L, Hackeng T, **Weber C**, Soehnlein O (2013) Neutrophil-derived cathelicidin promotes adhesion of classical monocytes, ***Circ. Res.*** 112:792-801. (***IF 11.089***)

88. ° Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhe Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, **Weber C**, Schober A (2012) MicroRNA-155 promotes atherosclerosis by derepressing Bcl6 in macrophages. ***J. Clin. Invest.*** 122:4190-4202. *(**IF 12.812,** 552 citations)*

89. Postea O, Vasina EM, Cauwenberghs S, Projahn D, Liehn EA, Lievens D, Theelen W, Kramp BK, Butoi E, Soehnlein O, Heemskerk JWM, Ludwig A, **Weber C***, Koenen RR* (2012) Role of platelet CX3CR1 in monocyte recruitment to arterial lesions. ***Arterioscler. Thromb. Vasc. Biol.*** 32:1186-1193. *equal contribution. *(**IF 6.338**)*

90. Döring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, Vijayan S, Gallo R, **Weber C**, Söhnlein O (2012) Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. ***Circ. Res.*** 110:1052-6. (***IF 11.861***)

91. Döring Y, Manthey H, Drechsler M, Lievens D, Manca M, Hartwig H, Busch M, Koenen RR, Soehnlein O, Zenke M, Daemen M, Lutgens E, **Weber C**, Zernecke A (2012) Autoantigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. ***Circulation*** 125:1673-83. *(**IF 15.202**, 381 citations)*

92. Grommes J, Alard JE, Drechsler M, Wantha S, Mörgelin M, Kuebler W, Jacobs M, von Hundelshausen P, Markart P, Preissner KT, Hackeng TM, Koenen RR, **Weber C**, Soehnlein O (2012) Disruption of platelet-derived chemokine heteromers abolishes endotoxin-induced lung injury. ***Am. J. Resp. Crit. Care Med.*** 185:628-36. *(**IF 11.041**)*

93. Liehn E, Tuchscheerer N, Kanzler I, Drechsler M, Fraemohs L, Schuh A, Koenen R, Zandler S, Soehnlein O, Hristov M, Grigorescu G, Urs A, Leabu M, Bucur I, Merx M, Zernecke A, Bernhagen J, Schober A, **Weber C** (2011) Double-edged role of the CXCL12-CXCR4 axis in experimental myocardial infarction. ***J. Am. Coll. Cardiol.*** 58:2415-23. (comment in *J. Am. Coll. Cardiol.* 58:2424-2426) (***IF 14.156***)

94. Soehnlein O, Wantha S, Simsekyilmaz S, Doering Y, Megens RT, Mause SF, Drechsler M, Smeetz R, Weinandy S, Schreiber F, Gries T, Vijayan S, van Zandvoort M, Agerberth B, Pham CT, Gallo RL, Hackeng TM, Liehn EA, Hristov M, Zernecke A, Klee D, **Weber C** (2011) Neutrophil-derived cathelicidin protects from neointimal hyperplasia. ***Sci. Transl. Med.*** 3:103ra98. (comment in *Nat. Rev. Drug Discov.* 2011;11:902; *SciBX* 2011;1227) (***IF 7.804***)

95. **Weber C**, Meiler S, Döring Y, Koch M, Drechsler M, Megens R, Rowinska Z, Bidzhekov K, Fecher C, Ribechini E, van Zandvoort M, Binder C, Jelinek Y, Hristov M, Boon L, Jung S, Korn T, Lutz MB, Förster I, Zenke M, Hieronymus T, Junt T, Zernecke A (2011) CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T-cell homeostasis in mice. ***J. Clin. Invest.*** 121:2898–2910. (***IF 13.069***, *287 citations)*

96. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, Heyll K, Reinholz M, van Zandvoort M, **Weber C**, Schober A (2011) Lipoprotein-derived lysophosphatidic acid enhances atherosclerosis through the release of CXCL1 from endothelium. ***Cell Metab.*** 13:592-600. ***(IF 13.668)***

97. Schober A, Hristov M, Forbrig R, Kofler S, Löhr B, Schumann U, Krötz F, Leibig M, König A, Kazcmerek I, Reichart B, Klauss V, **Weber C**, Sohn HY (2011) $CD34^{+}CD140b^{+}$ cells and CXCL12 predict the severity of cardiac allograft vasculopathy. ***Eur. Heart J.*** 32:476-84. *(**IF 10.478**)*

98. de Jager SC, Bermúdez B, Bot I, Koenen RR, Bot M, Kavelaars A, de Waard V, Heijnen CJ, Muriana FJ, **Weber C**, van Berkel TJ, Kuiper J, Lee SJ, Abia R, Biessen EA (2011) Growth differentiation factor-15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. ***J. Exp. Med.*** 208:217-25. (***IF 13.853***)

99. Ren M, Guo Q, Guo L, Lenz M, Qian F, Koenen RR, Xu H, Schilling AB, **Weber C**, Ye RD, Dinner AR, Tang WJ (2010) Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin degrading enzyme. ***EMBO J.*** 29:3952-3966. (***IF 10.124***)

100. Liehn EA, Piccinini A, Koenen RR, Soehnlein O, Adage T, Fatu R, Curaj A, Popescu A, Zernecke A, Kungl A, **Weber C** (2010) A potent CCL2 antagonist suitable for combined treatment of vascular and ischemia-reperfusion injury. ***J. Am. Coll. Cardiol.*** 56:1847-57. *(**IF 14.293**)*

101. Lievens D, Zernecke A, Seijkens T, Beckers L, Munnix ICA, Wijnands E, Flavell RA, Noelle RJ, Biessen EA, Daemen MJAP, Heemskerk JWM, **Weber C**, Lutgens E (2010) Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. ***Blood*** 116:4317-27. *(**IF 10.558**)*

102. ° Drechsler M, Megens R, van Zandvoort M, **Weber C**, Soehnlein O (2010) Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis in mice. ***Circulation*** 122:1837-45. *(**IF 14.432,** 749 citations)*

103. Berres ML, Rueland A, Koenen RR, Moreno Zaldivar M, Schmitz P, Streetz KL, Gassler N, Weiskirchen R, **Weber C**, Trautwein C, Wasmuth HE (2010) Antagonism of the chemokine CCL5 (RANTES) ameliorates experimental liver fibrosis *in vivo.* ***J. Clin. Invest.*** 120:4129-40. *(**IF 14.152**)*

104. Shagdarsuren E, Bidzhekov K, Mause S, Simsekyilmaz S, Polakowski T, Hawlisch H, Gessner JE, Zernecke A, **Weber C** (2010) C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. ***Circulation*** 122:1026-1036. *(**IF 14.432**)*

105. Goossens P, Gijbels MJJ, Zernecke A, van der Made I, Beckers L, Buurman WA, Daemen MJ, Kalinke U, **Weber C**, Lutgens E, de Winther MP (2010) Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. ***Cell Metab.*** 12:142-153. *(**IF 18.207**)*

106. Mause SF, Ritzel E, Liehn EA, Hristov M, Bidzhekov K, Mueller-Newen G, Soehnlein O, **Weber C** (2010) Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. ***Circulation*** 122:495-506. *(**IF 14.432**)*

107. Subramanian P, Karshovska E, Reinhard P, Zhou Z, Megens RTA, Akhtar S, Li X, van Zandvoort M, Ludin C, **Weber C**, Schober A (2010) Lysophosphatidic acid receptors LPA_1 and LPA_3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. ***Circ. Res.*** 107:96-105. *(**IF 9.504**)*

108. Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, de Winther M, Engel S, Seijkens T, Boon L, Ahonen C, Noelle R, Daemen M, Biessen EA, **Weber C** (2010) Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis and skews the immune response towards an anti-inflammatory profile. ***J. Exp. Med.*** 207:391-404. (***IF 14.776***)

109. Hristov M, Gümbel D, Shagdarsuren E, Lutgens E, Zernecke A, **Weber C** (2010) Soluble CD40 ligand impairs peripheral blood angiogenic outgrowth cell function and increases neointima formation after arterial injury. ***Circulation*** 121:315-324. (comment in *Circulation* 121:197-199) *(**IF 14.432**)*

110. ° Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Nazari Jahantigh M, Lutgens E, Wang S, Olson EN, Schober A, **Weber C** (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. ***Sci. Signal.*** 2:ra81. (comment in *Science* 326:1590) *(**IF 6.354,** 1541 citations)*

111. ° Karlmark KR, Weiskirchen R, Henning W. Zimmermann HW, Gassler N, Ginhoux F, **Weber C**, Merad M, Luedde T Trautwein C, Tacke F (2009) Hepatic recruitment of the inflammatory $Gr1^+$ monocyte subset upon liver injury promotes hepatic fibrosis. ***Hepatology*** 50:261-274. *(**IF 10.840**, 839 citations)*

112. Koenen RR, Pruessmeyer J, Soehnlein O, Fraemohs L, Zernecke A, Schwarz N, Reiss K, Lindbom L, **Weber C**, Ludwig A (2009) Regulated release and functional modulation of junctional adhesion molecule-A by disintegrin metalloproteinases. ***Blood*** 113:4799-809. *(**IF 10.555**)*

113. Matthijsen RA, de Winther MP, **Weber C**, Herias V, Gijbels MJ, Buurman WA (2009) Macrophage specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. ***Circulation*** 119:2188-95. *(**IF 14.816**)*

114. ° Landsman L*, Ber-On L*, Zernecke A*, Kim K, Krautgamer R, Shagdarsuren E, Lira SA, Weisman IL, **Weber C**, Jung S (2009) CX3CR1-mediated cell survival in monocyte homeostasis and atherogenesis. ***Blood*** 113:963-972. (comment in ***Blood*** 113:767-768) *equal contribution. *(**IF 10.555**, 527 citations)*

115. ° Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp B, Piccinini A, Kowalska A, Kungl A, Hackeng TM, Mayo KH, **Weber C** (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. ***Nat. Med.*** 15:97-103. *(**IF 27.136,** 492 citations)*

116. Choi EY, Chavakis E, Czabanka MA, Langer H, Fraemohs L, Economopoulou M, Orlandi A, Kundu RK, Zheng YY, Ballantyne CM, Constant SL, Aird W, Papayannopoulou T, Gahmberg C, Udey MC, Vajkoczy P, Quertermous T, Dimmeler S, **Weber C**, Chavakis T (2008) Del-1 is an endogenous inhibitor of leukocyte-endothelial adhesion preventing inflammatory cell recruitment. ***Science*** 322:1101-4. (comment in *Nat. Rev. Immunol.* 9:6-7) *(**IF 28.103**)*

117. **Weber C**, Kraemer S, Drechsler M, Lue H, Koenen R, Kapurniotu A, Zernecke A, Bernhagen J (2008) Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. ***Proc. Natl. Acad. Sci. USA.*** 105:16278-16283. *(**IF 9.380**)*

118. Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, **Weber C**, Lindbom L (2008) Neutrophil secretion products pave the way for inflammatory monocytes. ***Blood*** 112:1461-71. *(**IF 10.432**)*

119. Vogt F, Zernecke A, Beckner M, Krott N, Bosserhoff AK, Hoffmann R, Jahnke T, Kelm M, **Weber C**, Blindt R (2008) Blocking of angio-associated migratory cell protein inhibits smooth muscle cell migration and neointima formation after vascular injury in hyperlipidemic apolipoprotein E knock-out mice. ***J. Am. Coll. Cardiol.*** 52:302-11. (comment in *J. Am. Coll. Cardiol.* 52:312–314) *(**IF 11.438**)*

120. Frommhold D, Ludwig A, Bixel G, Zarbock A, Babushkina I, Lange-Sperandio B, Ellies LG, Marth JD, Beck-Sickinger AG, Linderkamp O, Zernecke A, **Weber C**, Vestweber D, Ley K, Sperandio M (2008) Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation. ***J. Exp. Med.*** 205:1435-46. *(**IF 15.463**)*

121. ° Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Meiler S, Liehn EA, Schober A, Soehnlein O, Sperandio M, Tacke F, Biessen EA, **Weber C** (2008) Protective role of Cxcr4/Cxcl12 unveils the importance of neutrophils in atherosclerosis. ***Circ. Res.*** 102:209-217. (comment in *Circ. Res.* 102:154-156) ***(IF 9.721,** 503 citations)*

122. Shagdarsuren E, Bidzhekov K, Liehn EA, Djalali-Talab Y, Hristov M, Matthijsen RA, Buurman WA, Zernecke A, **Weber C** (2008) C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. ***Circulation*** 117:70-78. ***(IF 12.755)***

123. Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, Liehn EA, van Santbrink PJ, Nelson PJ, Biessen EA, Mertens PR, **Weber C** (2007) YB-1 controls CCL5 expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. ***Circulation*** 116:1812-20. ***(IF 12.755)***

124. Galkina E, Harry B, Ludwig A, Liehn E, Sanders J, Bruce A, **Weber C**, Ley K (2007) CXCR6 promotes atherosclerosis by supporting T cell homing, interferon-γ production and macrophage accumulation in the aortic wall. ***Circulation*** 116:1801-1811. ***(IF 12.755)***

125. Bot I, de Jager SCA, Zernecke A, **Weber C**, van Berkel TJ, Biessen EA (2007) Perivascular mast cell activation aggravates atherogenesis and contributes to plaque destabilization in ApoE$^{-/-}$ mice. ***Circulation*** 115:2516-2525. (comment in *Circulation* 115:2471) ***(IF 12.755**, 357 citations)*

126. ° Bernhagen J, Krohn R, Lue H, Gregory J, Zernecke A, Koenen R, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, **Weber C** (2007) MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. ***Nat. Med.*** 13:587-596. (comment in *Nat. Rev. Drug Dis.* 6:435) ***(IF 26.382,** 1375 citations)*

127. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, **Weber C** (2007) Importance of CXCR2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. ***Circ. Res.*** 100:590-597. ***(IF 9.721)***

128. Braunersreuther V, Zernecke A, Steffens S, Burger F, Pelli G, Luckow B, Mach F, **Weber C** (2007) CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. ***Arterioscler. Thromb. Vasc. Biol.*** 27:373-9. ***(IF 7.221**, 339 citations)*

129. Lucerna M, Zernecke A, de Nooijer R, de Jager S, Bot I, van der Lans C, Kholova I, van Berkel TJC, Ylä-Herttuala S, **Weber C**, Biessen EAL (2007) Vascular endothelial growth factor induces plaque expansion in ApoE knockout mice by promoting *de novo* leukocyte recruitment. ***Blood*** 109:122-129. (comment in *Blood* 109:2-3) ***(IF 10.896)***

130. Zernecke A*, Liehn EA*, Gao JL, Murphy PM, Kuziel WA, **Weber C** (2006) Deficiency in CCR5 but not in CCR1 protects from neointima formation in atherosclerosis-prone mice: involvement of IL-10. ***Blood***. 107:4240-4243. * equal contribution. ***(IF 10.370)***

131. Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, Seitz B, Kapurniotu A, Kwok C, Dewor M, Bosserhoff AK, Bernhagen J, Hanrath P, Hoffmann R, **Weber C** (2006) A novel drug-eluting stent coated with an integrin-binding cRGD peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. ***J. Am. Coll. Cardiol.*** 47:1786-1795. ***(IF 9.701)***

132. Zernecke A, Bidzhekov K, Özüyaman B, Liehn EA, Fraemohs L, Firzlaff-Lüscher J, Lüscher B, Schrader J, **Weber C** (2006) CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. ***Circulation*** 113:2120-27 ***(IF 10.940)***

133. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, **Weber C** (2005) Statin treatment after onset of sepsis in a murine model improves survival, ***Circulation*** 112:117-124. (***IF 11.632**)*

134. Mause SF, von Hundelshausen P, Zernecke A, Koenen R, **Weber C** (2005) Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on inflamed and atherosclerotic endothelium. ***Arterioscler. Thromb. Vasc. Biol.*** 25:1512-18. ***(IF 7.053**, 459 citations)*

135. Zernecke A, Schober A, von Hundelshausen P, Liehn EA, Möpps B, Mericskay M, Gierschik P, Biessen EA, **Weber C** (2005) SDF-1α/CXCR4 axis is instrumental for neointimal hyperplasia and recruitment of smooth muscle cell progenitors. ***Circ. Res.*** 96:784-791. ***(IF 9.408,** 456 citations)*

136. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Proudfoot AEI, Adriaens W, Hackeng TM, **Weber C** (2005) Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. ***Blood*** 105:924-930. *(**IF 10.131**, 409 citations)*

137. Schober A, Zernecke A, Liehn E, von Hundelshausen P, Knarren S, Kuziel WA, **Weber C** (2004) The crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in atherosclerosis-prone mice involves early monocyte recruitment and CCL2 presentation on platelets. ***Circ. Res.*** 95:1125-1133. *(**IF 9.972**)*

138. Merx MW, Lin EA, Janssens U, Lütticken R, Schrader J, Hanrath P, **Weber C** (2004) HMG-CoA-reductase inhibitor simvastatin profoundly improves survival in sepsis. ***Circulation*** 109:2560-2565. *(**IF 12.563**, 341 citations)*

139. Zeiffer U, Schober A, Lietz M, Liehn EA, Erl W, Emans N, Yan ZQ, **Weber C** (2004) Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. ***Circ. Res.*** 94:776-784. (comment in *Circ. Res.* 94:706) *(**IF 9.972**)*

140. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, **Weber C** (2004) Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. ***Circulation*** 109:380-5. *(**IF 12.563**)*

141. Schober A, Knarren S, Lin E, Lietz M, Guttenbach M, **Weber C** (2003) Crucial role of stromal cell-derived factor-1α in neointima formation after arterial injury in apolipoprotein E-deficient mice. ***Circulation*** 108:2491-2497. *(**IF 11.164**)*

142. Baltus T, Weber KSC, Johnson Z, Proudfoot AEI, **Weber C** (2003) Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes. ***Blood*** 102:1085-88. *(**IF 10.120**)*

143. ° Huo YQ, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, **Weber C**, Ley K (2003) Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. ***Nat. Med.*** 9:61-67. *(**IF 30.550,** 1247 citations)*

144. Schober A, Manka D, von Hundelshausen P, Huo YQ, Hanrath P, Sarembock IJ, Ley K, **Weber C** (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. ***Circulation*** 106:1523-1529 (comment in *Circulation* 106:1433). *(**IF 10.255,** 414 citations)*

145. ° Ostermann G, Weber KSC, Zernecke A, Schröder A, **Weber C** (2002) JAM-1 is a ligand for the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. ***Nat. Immunol.*** 3:151-158 (comment in *Nat. Immunol.* 3:116). *(**IF 27.868,** 794 citations)*

146. Huo YQ, **Weber C**, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K (2001) The chemokine KC but not MCP-1 triggers arrest of monocytes in carotid arteries with early atherosclerotic lesions. ***J. Clin. Invest.*** 108:1307-14 (see also *J. Clin. Invest.* 108:1269). *(**IF 14.118,** 344 citations)*

147. Weber KSC, Ostermann G, Zernecke A, Schröder A, Klickstein LB, **Weber C** (2001) Dual role of H-ras in regulation of LFA-1 activity by SDF-1α: implications for leukocyte transmigration. ***Mol. Biol. Cell*** 12:3074-3086. *(**IF 7.700**)*

148. von Hundelshausen P, Weber KSC, Huo YQ, Proudfoot A, Nelson PJ, Ley K, **Weber C** (2001) Deposition of RANTES by platelets triggers monocyte recruitment on inflamed and atherosclerotic endothelium. ***Circulation*** 103:1772-1777 (comment in *Circulation* 103:1718). *(**IF 10.517,** 727 citations)*

149. **Weber C**, Weber KSC, Klier C, Gu H, Horuk R, Wank R, Nelson PJ (2001) Specialized roles of the chemokine receptors CCR1 and CCR5 in recruitment of monocytes and Th1-like/CD45RO$^+$ T cells. ***Blood*** 97:1144-1146 (comment in *Blood* 97:833). *(**IF 9.273**)*

150. **Weber C**, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, Frankenberger M, Weber KSC, Ziegler-Heitbrock HWL (2000) Differential chemokine receptor expression and function in human monocyte subpopulations. ***J. Leukoc. Biol.*** 67:699-704. *(**IF 4.342,** 507 citations)*

151. Weber KSC, Nelson PJ, Gröne HJ, **Weber C** (1999) Expression of CCR2 by endothelial cells: implications for MCP-1-mediated wound injury repair and in vivo inflammatory activation of endothelium. ***Arterioscler. Thromb. Vasc. Biol.*** 19:2085-2093. *(**IF 5.406,** 338 citations)*

152. Weber KSC, Draude G, Erl W, de Martin R, **Weber C** (1999) Monocyte arrest and transmigration on inflamed endothelium in shear flow is inhibited by adenoviral gene transfer of IκB-α. ***Blood*** 93:3685-3693. *(**IF 8.782**)*

153. Weber KSC, Klickstein LB, **Weber C** (1999) Specific activation of the β2 integrins Mac-1 and LFA-1 by chemokines in mononuclear cells mediated by distinct activation pathways via the α subunit cytoplasmic domains. ***Mol. Biol. Cell.*** 10:861-873. ***(IF 7.527)***

154. Erl W, Hansson GK, de Martin R, Draude G, Weber KSC, **Weber C** (1999) Nuclear factor-κB regulates apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. ***Circ. Res.*** 84:668-677. ***(IF 8.281)***

155. Piali L, **Weber C**, La Rosa G, Mackay CR, Springer TA, Clark-Lewis I, Moser B (1998) The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. ***Eur. J. Immunol.*** 28:961-972. ***(IF 5.438)***

156. **Weber C**, Erl W, Weber KSC, Weber PC (1997) HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from hypercholesterolemic patients. ***J. Am. Coll. Cardiol.*** 30:1212-1217 (comment in *J. Am. Coll. Cardiol.* 30:1218). ***(IF 6.704,*** *557 citations)*

157. **Weber C**, Springer TA (1997) Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to αIIbβ3 and stimulated by platelet activating factor. ***J. Clin. Invest.*** 100:2085-2093. ***(IF 9.667,*** *424 citations)*

158. **Weber C**, Kitayama J, Springer TA (1996) Differential regulation of β1 and β2 integrin avidity by chemo-attractants in eosinophils. ***Proc. Natl. Acad. Sci. USA.*** 93: 10939-944. (***IF 9.040***)

159. **Weber C**, Alon R, Moser B, Springer TA (1996) Sequential regulation of α4β1 and α5β1 integrin avidity by CC chemokines in monocytes: Implications for transendothelial chemotaxis. ***J. Cell Biol.*** 134:1063-1073. (***IF 12.005,*** *292 citations)*

160. **Weber C**, Erl W, Weber K, Weber PC (1996) Increased adhesiveness of isolated monocytes to en-dothelium is prevented by vitamin C intake in smokers. ***Circulation*** 93:1488-492. (***IF 9.762***)

161. **Weber C**, Erl W, Pietsch A, Weber PC (1995) Aspirin inhibits NF-κB mobilization and monocyte adhesion in stimulated human endothelial cells. ***Circulation.*** 91:1914-1917. (***IF 9.762,*** *346 citations)*

162. **Weber C**, Erl W, Pietsch A, Ströbel M, Ziegler-Heitbrock HWL, Weber PC (1994) Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-κB mobilization and induction of vascular cell adhesion molecule 1 in endothelial cells stimulated to generate radicals. ***Arterioscler. Thromb. Vasc. Biol.*** 14:1665-1673. (***IF 5.317,*** *402 citations)*

Review articles (°Clarivate top 1% in subject area)

1. Döring Y, van der Vorst EPC, **Weber C** (2024) Targeting immune cell recruitment in atherosclerosis. ***Nat. Rev. Cardiol.***, in press.
2. Mohanta S, Santovito D, **Weber C** (2024) Cortico-limbic restructuring and atherosclerosis: a stressful liaison. ***Eur. Heart J.***, in press. *(**IF 39.3**)*
3. **Weber C**, Habenicht A, von Hundelshausen P (2023) Novel mechanisms and therapeutic targets in atherosclerosis: beyond inflammation. ***Eur. Heart J.*** 44:2672-2681. (***IF 39.9***)
4. Farina F, **Weber C***, Santovito D* (2023) Non-canonical functions of noncoding RNAs in atherosclerosis. ***Atherosclerosis*** 374:74-86. *corresponding authors. *(**IF 5.3**)*
5. Bonfiglio C, **Weber C**, Atzler D, Lutgens E (2023) Immunotherapy and cardiovascular diseases (CVD): novel avenues for immunotherapeutic approaches. ***QJM*** 116:271-278. *(**IF 13.3**)*
6. Farina F, Santovito D, **Weber C** (2022) Two-faced Janus: CCR2 macrophages and their dual role in allograft rejection in the transplanted heart. ***Circulation*** 146:639-642. *(**IF 39.918**)*
7. Evans PC, Davidson S, Wojta J, Bäck M, Bollini S, Brittan M, Catapano A, Chaudhry B, Cluitmans M, Gnecchi N, Guzik T, Höfer I, Madonna R, Morawietz H, Osto E, Padró T, Sluimer J, Tocchetti CG, Van der Heiden K, Garcia Vilahur G, Waltenberger J, **Weber C** (2022). Basic Cardiovascular Science Highlights of 2021-2022. ***Cardiovasc. Res.*** 118:2754-2767. *(**IF 13.081**)*
8. Santovito D, **Weber C** (2022) Noncanonical features of microRNAs: paradigms emerging from cardiovascular disease. ***Nat. Rev. Cardiol.*** 19:620-638. *(**IF 49.421**)*
9. Davidson S, Prado T, Bollini S, Vilahur G, Duncker D, Evans P, Guzik T, Hoefer I, Waltenberger J, Wojta J, **Weber C** (2021) The year in basic cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart. ***Cardiovasc. Res.*** 117:2161-2174. *(**IF 13.081**)*
10. Evans P, Wojta J, Hoefer IE, Waltenberger J, Guzik T, Badimon L, **Weber C** (2021) The year in basic vascular biology research: from smartphone data and omics to mechanoreceptors and NETs. ***Cardiovasc. Res.*** 117:1814-1822. *(**IF 13.081**)*
11. **°** von Hundelshausen P, Lorenz R, Siess W, **Weber C** (2021) Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. ***Thromb. Haemost.*** 121:1395-1399. *(**IF 6.6830**)*
12. Döring Y, Noels H, van der Vorst E, **Weber C** (2020) Seeing is repairing – how imaging-based timely interference with CXCR4 could improve repair after myocardial infarction. ***Eur. Heart J.*** ehaa625. (***IF 29.983***)*
13. Bartelt A, **Weber C** (2020) Mitochondrial ejection for cardiac protection: the macrophage connection. ***Cell Metabol.*** 32:512-513. *(**IF 27.287**)*
14. **°** Evans PC, Rainger GE, Mason JC, Guzik TJ, Stamataki Z, Hoefer I, Waltenberger J, **Weber C**, Bochaton-Piallat ML, Bäck M (2020) Endothelial dysfunction in COVID-19. ***Cardiovasc. Res.*** 116:2177-2184. *(**IF 10.787**)*
15. Lutgens E, Atzler D, Döring Y, Duchene J, Steffens S, **Weber C** (2019) Immunotherapy for cardiovascular disease. ***Eur. Heart J.*** 40:3937-3946. (***IF 22.673***)*
16. Bartelt A, Leipsic J, **Weber C** (2019) The new age of radiomic risk profiling: perivascular fat at the heart of the matter. ***Eur. Heart J.*** 40:3544-3546. (***IF 22.673***)*
17. Lacy M, Atzler D, de Winther M, **Weber C**, Lutgens E (2019) Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis. ***Pharmacol. Ther.*** 193:50-62. *(**IF 10.557**)*
18. Ketelhuth DFJ, Lutgens E, Bäck M, Binder CJ, Van den Bossche J, Daniel C, Dumitriu IE, Hoefer I, Libby P, O'Neill L, **Weber C**, Evans P (2019) Immunometabolism and atherosclerosis: perspectives and clinical significance – A position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. ***Cardiovasc. Res.*** 115:1385-1392. *(**IF 8.168**)*
19. Tuñón J, Bäck M, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen M, Egido J, Evans PC, Francis SE, Ketelhuth D, Lutgens E, Matter C, Monaco C, Steffens C, Stroes E, Vindis C, **Weber C**, Hoefer IE on behalf of

the ESC Working Group on Atherosclerosis and Vascular Biology (2019) Identifying the anti-inflammatory response to lipid lowering therapy. ***Cardiovasc. Res.*** 115:10-19. *(**IF 8.168**)*

20. Poller W, Dimmeler S, Heymans S, Zeller T, Haas J, Karakas M, Leistner DM, Jakob P, Nakagawa S, Blankenberg S, Engelhardt S, Thum T, **Weber C**, Meder B, Hajjar R, Landmesser U (2018) Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. ***Eur. Heart J.*** 39:2704-2716. (***IF 23.425***)
21. van der Vorst EPC, **Weber C** (2018) Metabolomic profiling of atherosclerotic plaques: towards improved cardiovascular risk stratification. ***Eur. Heart J.*** 39:2311-2313. (***IF 24.889***)
22. **°** **Weber C**, von Hundelshausen P (2017) CANTOS trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting. ***Circ. Res.*** 121:1119-1121. *(**IF 15.211**)*
23. Soehnlein O, Steffens S, Hidalgo A, **Weber C** (2017) Neutrophils as protagonists and targets in chronic inflammation. ***Nat. Rev. Immunol.*** 17:248-261. *(**IF 41.982**, 399 citations)*
24. Doering Y, Soehnlein O, **Weber C** (2017) Neutrophil extracellular traps in atherosclerosis and atherothrombosis. ***Circ. Res.*** 120:736-743. *(**IF 15.211**)*
25. **Weber C**, Shantsila E, Hristov M, Caligiuri G, Guzik T, Heine GH, Hoefer I, Monaco C, Peter K, Rainger E, Siegbahn A, Steffens S, Woyta J, Ziegler-Heitbrock L, Lip GYHL (2016) Role and analysis of monocyte subsets in cardiovascular disease: joint position paper of the ESC WG on Atherosclerosis & Vascular Biology and the ESC WG on Thrombosis. ***Thromb. Haemost.*** 116:626-37. *(**IF 5.627**)*
26. Schober A, **Weber C** (2016) Mechanisms of microRNAs in atherosclerosis. ***Ann. Rev. Pathol.*** 11:583-616. *(**IF 26.853**)*
27. Hoefer IE, Steffens S, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, Boulanger CM, Caligiuri G, Dimmeler S, Egido J, Evans PC, Guzik T, Kwak BR, Landmesser U, Mayr M, Monaco C, Pasterkamp G, Tuñón J, **Weber C** (2015) Novel methodologies for biomarker discovery in atherosclerosis. ***Eur. Heart J.*** 36:2635-42. *(**IF 15.064**)*
28. Bäck M, **Weber C**, Lutgens E (2015) Regulation of atherosclerotic plaque inflammation. ***J. Intern. Med.*** 278:462-82. *(**IF 7.803**)*
29. Hartmann P, Schober A, **Weber C** (2015) Chemokines and miRNAs in atherosclerosis. ***Cell. Mol. Life Sci.*** 72:3253-66. *(**IF 5.694**)*
30. Megens R, Bianchini M, Schmitt M, **Weber C** (2015) Optical imaging innovations for atherosclerosis research: multiphoton microscopy and optical nanoscopy. ***Arterioscler. Thromb. Vasc. Biol.*** 35:1339-46. *(**IF 5.969**)*
31. Schober A, Nazari-Jahantigh M, **Weber C** (2015) Mechanisms of microRNAs in atherosclerosis. ***Nat. Rev. Cardiol.*** 12:361-374. *(**IF 10.533**)*
32. Santovito D, Egea V, **Weber C** (2015) DNA methylation and epigenetics: exploring the terra incognita of the atherosclerotic landscape. ***Eur. Heart J.*** 36:956-8. *(**IF 15.064**)*
33. Kwak B, Back M, Bochaton-Piallat ML, Caligiuri G, Daemen MAJ, Davies P, Hoefer I, Holvoet P, Krams R, Monaco C, Steffens S, Virmani R, **Weber C**, Wentzel J, Evans PC (2014) Biomechanical factors in atherosclerosis: mechanisms and clinical implications. ***Eur. Heart J.*** 35:3013-3020. *(**IF 15.203**)*
34. Mohanta SK, Yin C, Peng L, Srikakulapu P, Bontha V, Hu D, Weih F, **Weber C**, Gerdes N, Habenicht AJR (2014) Artery tertiary lymphoid organs control innate and adaptive immune responses in advanced mouse atherosclerosis during aging. ***Circ. Res.*** 114:1772-1787. *(**IF 11.019**)*
35. Silvestre-Roig C, de Winther MPJ, **Weber C**, Daemen MJ, Lutgens E, Soehnlein O (2014) Atherosclerotic plaque destabilization: mechanisms, models and therapeutic strategies. ***Circ. Res.*** 114:214-26. *(**IF 11.019**)*
36. Ylä-Herttuala S, Bentzon J, Daemen M, Falk E, Garcia H, Herrmann J, Hoefer I, Jukema J, Krams R, Kwak B, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys P, Waltenberger J, **Weber C**, Tokgözoglu L (2013) Stabilising atherosclerotic plaques: an update. ***Eur. Heart J.*** 34:3251-8. *(**IF 14.723**)*
37. Koenen RR, **Weber C** (2011) Chemokines: new targets in atherosclerosis. ***EMBO Mol. Med.*** 3:713-25. *(**IF 7.795**)*
38. **°** **Weber C**, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. ***Nat. Med.*** 17:1410-1422. *(**IF 22.462**, 2275 citations)*

39.° Mause SF, **Weber C** (2010) Microparticles - protagonists of a novel communication network for intercellular information exchange. ***Circ. Res.*** 107:1047-57. *(**IF 9.504**, 941 citations)*

40. **Weber C** (2010) Far from the heart: receptor cross-talk in remote conditioning. ***Nat. Med.*** 16:760-2. *(**IF 25.430**)*

41. Koenen RR, **Weber C** (2010) Therapeutic targeting of chemokine interactions in atherosclerosis. ***Nat. Rev. Drug Discov.*** 9:141-53. *(**IF 28.712**)*

42. Soehnlein O, Lindbom L, **Weber C** (2009) Neutrophils and the control of monocyte extravasation. ***Blood*** 114:4613-23. *(**IF 10.555**)*

43. Zernecke A, Shagdarsuren E, **Weber C** (2008) Chemokines in atherosclerosis: an update. ***Arterioscler. Thromb. Vasc. Biol.*** 28:1897-1908. *(**IF 6.858,** 519 citations)*

44. **Weber C**, Zernecke A, Libby P (2008) The multifacetted contributions of leukocyte subsets to atherosclerosis. ***Nat. Rev. Immunol.*** 8:802-815. *(**IF 30.006,** 958 citations)*

45. Zernecke A, Bernhagen J, **Weber C** (2008) Macrophage migration inhibitory factor in cardiovascular disease. ***Circulation*** 117:1594-1602. *(**IF 14.595**)*

46. Merx MW, **Weber C** (2007) Sepsis and the heart. ***Circulation*** 116:782-792. *(**IF 12.755**, 575 citations)*

47. **Weber C**, Fraemohs L, Dejana E (2007) The role of junctional adhesion molecules in vascular inflammation. ***Nat. Rev. Immunol.*** 7:467-477. *(**IF 28.300,** 591 citations)*

48. von Hundelshausen P, **Weber C** (2007) Platelets as immune cells: bridging inflammation and vascular disease. ***Circ. Res.*** 100:27-40. *(**IF 9.721,** 825 citations)*

49. **Weber C**, Koenen R (2006) Fine-tuning leukocyte responses: towards a chemokine interactome. ***Trends Immunol.*** 27:268-73. *(**IF 10.213**)*

50. Merx M, **Weber C** (2006) Statins: a preventive strike against infection-related mortality in patients with cardiovascular disease? ***Lancet*** 367:372-373. *(**IF 25.800**)*

51. **Weber C** (2005) Plalelets and chemokines in atherosclerosis: partners in crime. ***Circ. Res.*** 96:612-616. *(**IF 9.408**)*

52.° Zernecke A, **Weber C** (2005) Inflammatory mediators of atherosclerotic vascular disease. ***Basic Res. Cardiol.*** 100:93-101. *(**IF 2.806**)*

53. Hristov M, **Weber C** (2004) Endothelial progenitor cells: pathophysiological aspects and possible clinical relevance. ***J. Cell. Mol. Med.*** 8:498-508. *(**IF 2.153,** 642 citations)*

54. **Weber C**, Zernecke A, Schober A (2004) Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. ***Arterioscler. Thromb. Vasc. Biol.*** 24:1997-2008. *(**IF 7.432**)*

Invited key note and plenary lectures (selection)

1. **Weber C** (2023) Chemokine signaling in atherosclerosis – from mechanisms to translation. Keynote Lecture. European Atherosclerosis Society (EAS), Mannheim, Germany.
2. **Weber C** (2022) Novel mechansims and therapeutic targets in atherosclerosis. William Harvey Lecture in Basic Sceince. European Society of Cardiology (ESC), Barcelona, Spain.
3. **Weber C** (2021) Novel mechanisms and targets in atherosclerosis. XXII Lipid Meeting, Leipzig, Germany.
4. **Weber C** (2020) Nonocanonical functions of microRNAs in vascular disease. IVBM 2020, Seoul, South Corea.
5. **Weber C** (2019) Novel strategies for immunotherapy of atherosclerosis. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.
6. **Weber C** (2018) Inflammation: a treatment target in CAD prevention. ESC, Munich, Germany.
7. **Weber C** (2017) Targeting chemokines to control plaque cell infiltration. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.

8. **Weber C** (2017) Regulation of atherosclerosis by microRNAs. European Atherosclerosis Society (EAS) Congress 2017, Prag, Czech Republic.
9. **Weber C** (2016) Chemokine interactome mapping for tailored intervention in acute and chronic inflammation. Gordon Research Conference on *Chemotactic Cytokines*, Girona, Spain
10. **Weber C** (2015) Chemokines in atherosclerosis. GTH Congress 2015, Düsseldorf, Germany.
11. **Weber C** (2015) Regulation of microRNA trafficking in atherosclerosis. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.
12. **Weber C** (2014) miRNAs and regional susceptibility to atherosclerosis. FCVB 2014, Barcelona, Spain.
13. **Weber C** (2014) Chemokines and miRNAs and atherosclerosis. IVBM 2014, Kyoto, Japan
14. **Weber C** (2013) MicroRNAs and atherosclerosis: from molecular mechanism to potential clinical applications. President's Lecture, Italian Society of Atherosclerosis, Roma, Italy.
15. **Weber C** (2013) Targeting platelets in vascular inflammation. European Society of Cardiology (ESC), Amsterdam, Netherlands
16. **Weber C** (2013) Dendritic and regulatory T-cells in atherosclerosis. American Diabetes Association Congress 2013, Chicago, USA.
17. **Weber C** (2013) Emerging mechanisms of chemokine receptor control of atherosclerosis. The Ottawa Research Conference, Ottawa, Canada.
18. **Weber C** (2012) CXCL12 - is it important? AHA Scientific Sessions, Los Angeles, USA.
19. **Weber C** (2012) Therapeutic targeting of microRNAs in atherosclerosis. ESC, Munich, Germany.
20. **Weber C** (2012) Role of chemokines in cardiovascular disease. Gordon Research Conference on *Chemotactic Cytokines*, Il Ciocco, Italy.
21. **Weber C** (2012) Chemokines as therapeutic targets. Internat. Atherosclerosis Society 2012, Sydney, Australia.
22. **Weber C** (2011) Chemokines and their receptors as therapeutic targets in atherosclerosis. EMBO Molecular Medicine Conference: Molecular Insights for Innovative Therapies, Heidelberg, Germany.
23. **Weber C** (2011) The inflammatory pathogenesis of atherosclerosis. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
24. **Weber C** (2011) MicroRNAs - a novel target in cardiovascular prevention. ESC, Paris, France.
25. **Weber C** (2011) Chemokines as therapeutic targets in the treatment of atherosclerosis. 79th European Atherosclerosis Society (EAS) Congress, Gothenburg, Sweden.
26. **Weber C** (2011) Microparticles as transfer modules in cardiovascular disease. 6th European Meeting for Vascular Biology & Medicine (EVBVM), Krakow, Poland.
27. **Weber C** (2011) Role of inflammation in atherosclerosis. 10th World Congress in Inflammation. Paris, France.
28. **Weber C** (2010) Chemokines in the vascular inflammatory response. ESC, Stockholm, Sweden.
29. **Weber C** (2010) Chemokines as therapeutic targets in atherosclerosis. Kern Conferences, Aspen, USA.
30. **Weber C** (2010) Chemokines as crucial drivers of macrophage and dendritic cell function in atherosclerosis. International Vascular Biology Meeting (IVBM) 2010, Los Angeles, USA.
31. **Weber C** (2010) A miRNA-mediated mechanism for functional chemokine induction. Gordon Research Conference on *Chemotactic Cytokines*, Il Ciocco, Italy.
32. **Weber C** (2010) Role of chemokines for cell migration during inflammation. 8th World Congress on Trauma, Shock, Inflammation and Sepsis - TSIS 2010, Munich, Germany.
33. **Weber C** (2009) Progenitor cell trafficking in the vascular wall. International Society of Thrombosis and Haemostasis (ISTH) Meeting 2009, Boston, USA.
34. **Weber C** (2009) Chemokines as therapeutic targets in atherosclerosis. International Atherosclerosis Society (IAS) Meeting 2009, Boston, USA.
35. **Weber C** (2008) MIF as a pseudo-chemokine in atherosclerosis. AHA Scientific Sessions, New Orleans, USA.

36. **Weber C** (2008) Structural basis and *in vivo* relevance of chemokine heteromerization. Gordon Research Conference on *Chemotactic Cytokines*, Aussois, France.
37. **Weber C** (2008) The monocyte: function and fate. European Society of Cardiology (ESC), Munich, Germany.
38. **Weber C** (2008) Functional diversity of chemokines and mononuclear cell subsets in atherosclerosis. 77th European Atherosclerosis Society (EAS) Congress, Istanbul, Turkey.
39. **Weber C** (2008) Chemokines and chemokine-like ligands in vascular inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference 2008, Atlanta, USA.
40. **Weber C** (2008) Chemokine-like functions of MIF in leukocyte recruitment - Joint Lecture. Keystone Symposia Leukocyte Trafficking / Chemokines and Chemokine Receptors, Keystone, USA.
41. **Weber C** (2008) Chemokines: inflammatory mediators of atherosclerosis. 3rd Joint Meeting of French, German and Swiss Atherosclerosis Societies, St. Gervais, France.
42. **Weber C** (2007) Ambivalence of progenitor cells in vascular repair and plaque instability, Royal Netherlands Academy of Arts and Sciences, Amsterdam, Netherlands.
43. **Weber C** (2007) Role of EPCs in cardiovascular repair, European Society of Cardiology (ESC), Wien, Austria.
44. **Weber C** (2007) Basic Science Key Note - Cytokine in der Atherosklerose: Angriffspunkte für die therapeutische Intervention? 74th Annual Congress of the German Cardiac Society (DGK), Mannheim, Germany.
45. **Weber C** (2007) Chemokines & atherosclerosis, 7th World Congress Trauma, Shock, Inflammation & Sepsis TSIS 2007, Munich, Germany.
46. **Weber C** (2007) Platelet & inflammatory cell interactions. British Atherosclerosis Society, Glasgow, UK.
47. **Weber C** (2006) Cross-talk between blood cells in inflammation. European Society of Cardiology (ESC) and World Congress of Cardiology (WCC), Barcelona, Spain.
48. **Weber C** (2006) Chemokines in vascular cell recruitment, UK/German Adhesion Society, London, UK.
49. **Weber C** (2006) Chemokines in arterial pathology. Int. Vascular Biology Meeting, Amsterdam, Netherlands.
50. **Weber C** (2006) Cell-cell interactions in the vascular wall. III. Cardiovascular Healing Symposium, Leopoldina Akademie der Naturforscher, Würzburg, Germany.
51. **Weber C** (2005) Interplay of chemokines and platelets in vascular cell recruitment, 3rd European Vascular Biology Meeting (EVBM), Hamburg, Germany.
52. **Weber C** (2004) Platelet-derived mediators and atherosclerosis. AHA Scientific Sessions, New Orleans, USA.
53. **Weber C** (2004) Role of JAM-A in inflammatory & atherogenic leukocyte recruitment. Gordon Research Conference *Immunoglobulin Family Members in Infection, Immunity & Cancer*, Massachussetts, USA.
54. **Weber C** (2004) Role of chemokines in arteriogenesis and angiogenesis, Working Group Vascular Biology, 70th Annual Congress of the German Cardiac Society, Mannheim, Germany.
55. **Weber C** (2003) Novel molecular targets to modulate monocyte recruitment. Mario-Negri-Institute, Milan, Italy.
56. **Weber C** (2002) Involvement of JAM-1 as a newly identified ligand of LFA-1 in leukocyte transendothelial migration. 2nd Joint UK/German adhesion meeting, German Society of Immunology, Berlin, Germany.
57. **Weber C** (1998) Adhesion molecules, chemokines and the cytoskeleton in arteriosclerosis, Working group Pathogenesis Arteriosclerosis, 65th Annual Congress of the German Cardiac Society, Mannheim, Germany.
58. **Weber C** (1998) Antioxidant effects on monocyte-endothelial cell interactions & vascular cell apoptosis. FASEB Summer Research Conference *Mechanisms of Antioxidant Action*, Copper Mt., Colorado, USA.